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1 
Abstract 
 
Biomedical science has been greatly advanced and recognized as an important area to improve human 
healthcare. Recent advances in nanotechnology have been appreciated for developing biomedical 
sciences with its potential of generating unique materials, devices and systems utilizing phenomena 
and properties of nanoscale substances. The terminology, nanobiotechnology, is the combination of 
biotechnology and nanotechnology, and has been recognized as future promising technology. 
Nanobiotechnology usually represents a range of material size from 1 nm to 100 nm. Nanoscale 
materials have been widely utilized to observe physical, chemical and biological properties of 
substances. There are diverse nanomaterials including quantum dots (QDs), liposomes, dendrimers, 
virus-like particles (VLPs), and protein cages, utilized for biomedical applications. Biomedical 
applications can be generally classified into cell targeting, drug delivery, bioimaging, and vaccine 
development. In order to utilize nanoscale substances for such biomedical applications, their surface 
can be easily modifiable and they should contain optimal solubility and stability in aqueous media, 
without any side effects on biological properties and functionalities. Among the number of 
nanomaterials, protein cages such as ferritin, heat shock protein and Lumazine synthase have been 
highlighted with their advantages of biocompatibility, non-toxic, low cost for production and 
biodegradability, and applied for various biomedical sciences. Protein cages contain a hollow internal 
space which can encapsulate small molecules like fluorescence dyes or probes as a detector, and have 
an external surface which can be modifiable by using bioconjugation and azide-alkyne click chemistry. 
In this study, we focus on developing diverse protein cages for biomedical applications, particularly 
for cell targeting system.  
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Chapter1. Introduction 
 
1.1. Biomedical application 
 
1.1.1. Cell targeting 
For therapeutic and diagnostic purpose, cell targeting systems have to enable the optimal delivery of 
certain molecules into a specific target such as cancer cells, which ultimately reduces potential side 
effects and increases therapeutic/diagnostic efficiency for cancer patients. In order to enhance 
targeting efficiency, first, nanoscale assemblies need to be changed with physicochemical properties 
(surface topography and charge). Second, antibodies, peptides, nucleic acids (aptamers), small 
molecules, vitamins or carbohydrates are required for increasing targeting specificity via receptor-
mediated endocytosis.[1-3] Among the target moieties, antibody-based targeting method, the main 
clinical approach, is preferred due to its high specificity and affinity with few side effects and 
potential immunogenicity. However, antibody production cost is significantly high and it has 
limitation in clinical applicability.[4] Recently, aptamers, class of small nucleic acid ligands, show 
many advantages over protein antibodies, including simple chemical synthesis, virtual non-
immunogenicity, smaller size, faster tissue penetration, ease of modification with different functional 
moieties, low cost of production, and high biological stability.  
 
1.1.2. Drug delivery 
Many drugs are designed to minimize side effects and maximize therapeutic potential, but side effects 
of drugs due to their non-specificity are still hot issues in clinical treatment such as pharmacotherapy. 
[1]Selective delivery with high specificity is required, and nanoparticles offer great potential as a drug 
delivery system reducing drug toxicity, protecting drug degradation or sequestration and increasing 
circulation times, targeting efficiency, biocompatibility and bioavailability.[2, 4] Nanoparticles have a 
hollow cavity which can encapsulate drugs allowing low toxicity and water solubility, and their 
surfaces can be chemically or genetically modified to enhance targeting efficiency. Optimal size of 
nanomaterials enhances their retention time in the body, and as small drugs are encapsulated into 
nanoparticles, their size and morphology are evenly form by using nanoparticles as a template. [5]     
 
1.1.3. Bioimaging 
There are many bioimaging methods such as optical imaging and magnetic resonance imaging. These 
imaging techniques need a molecule for detection.[1] Small molecules with fluorescent dyes or other 
probes can be applied into the body for bioimaging, and the concentrations of dyes or probes at 
specific sites can be regulated via a bioconjugation method. They can be conjugated onto the surface 
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of nanomaterials or into the hollow cavity. However, small molecules for bioimaging have some 
issues such as non-specificity, instability, toxicity, fast clearance, time dependent low activity, and the 
limitation of surface modification.[1] In order to solve those problems, nanomaterials based 
bioimaging probes have been produced using biocompatible nanomaterials. The complex of 
nanomaterials and imaging probes has enhanced stability and reduced toxicity with low nonspecific 
binding. 
 
1.1.3.1. Optical imaging 
Fluorescent probes are widely utilized for optical imaging due to their stability and sensitivity. 
Particularly, NIR (near infrared) region, from 650nm to 900nm, is able to avoid some limitations such 
as light scattering, auto fluorescence, and absorption by tissues. The best NIR fluorescent agents 
should have fluorescence in NIR region, fine excitation/emission spectrum, and functional groups for 
modification. These agents take advantages such as stability, nontoxicity, biocompatibility, or 
biodegradability, but also there are many weaknesses such as low specificity, rapidly aggregation, 
photobleaching, and short half-life.[1, 6] When biocompatible nanomaterials are utilized with those 
imaging dyes or probes together, the weaknesses can be reduced. So, nanomaterials based imaging 
agents can generate better features such as enhanced stability, reduced toxicity, improved targeting 
efficiently, and reduced background.  
 
1.1.3.2. Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) detects the properties of hydrogen atoms in water and generates 
high quality images of the body, allowing MRI to be used in a wide range of medical applications.  In 
magnetic field, nuclei as charged particles are rotated and oscillated for returning to equilibrium.at 
time, nuclei release a radio signal and then detected as a body image. Proton density in tissue types 
determines image intensity. Also, it is important to tissue relaxation properties which are divided into 
T1 relaxation and T2 relaxation for image contrast. T1 relaxation, spin-lattice relaxation, recovers 
longitudinal magnetization because energy of nuclear spin system transfers to neighboring molecules. 
T2 relaxation, spin-spin relaxation, transverses magnetization decays because of dephasing of proton 
spins. MRI takes advantages such as non-invasive, nonionizing radiation, and high soft-tissue 
resolution. T1 agents are called paramagnetic or positive contrast agents which include Fe (iron), Mg 
(magnesium), and Gd (gadolinium).[6] T2 agents are called a super paramagnetic or negative contrast 
agent which includes magnetite (Fe3O4) or maghemite (γ-Fe2O3) water insoluble iron oxide. These 
contrast agents can obtain batter signal than surrounding tissues, accumulate in certain site, but have 
short imaging time, toxicity, low signal, and limitation of clinical application. To enhance a positive 
effect, combination with nanomaterials is necessary, providing advantage such as low toxicity, high 
retention time in the blood, and functional group modification.     
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1.1.4.  Vaccine development 
Vaccines are essential medical tools for human healthcare. Vaccines protect human beings from many 
diseases, but there are still a number of not-preventable diseases due to non-effective vaccines. 
[7]Vaccines are classified into two types: live-attenuated pathogen and inactivated /killed pathogens. 
Live-attenuated vaccines are highly immunogenic but have safety concerns and may provide trigger-
causing disease. On the other hand, inactivated or killed vaccine strains have weak immune reaction 
and practical limitation, which requires multiple times of administration.[1] Nanomaterials are 
expected to be utilized for enhancing vaccine efficacy with multi copy antigen display. 
 
1.2. Nanoscale materials 
 
1.2.1.  Polymers 
Poly (lactic-co-glycolic acid) (PLGA) approved by the US Food and Drug Administration (FDA) has 
an important role in medicine and pharmacy.[6] Multiple polymers are widely used in drug delivery 
systems, tissue engineering, regeneration medicine, and bioimaging. For drug delivery systems, 
polymer nanoparticles are developed with poly (norbornene) diblock copolymers via hydrogen 
bonding. Polymer nano capsules are synthesized by using traditional chemical reactions and have 
highly stable structure with diverse diameters from 60 to 600nm.[6] For example, chitosan, a cationic 
polysaccharide, has many advantages such as biodegradability, biodistribution, biocompatibility and 
non-toxicity, which is widely utilized as a drug delivery vehicle. 
  
1.2.2.  Liposomes 
Liposomes, lipid bilayer vesicles, consist of single or multiple lipid bilayers. When a bilayer consists 
of single lipid, liposomes are categorized as unilamellar vesicles which have range from 50 to 250 
nm., while multiple bilayers provide multi lamellar vesicles having a range from 500 to 5000 nm. 
[1]Liposomes have been used in drug delivery and imaging. Liposomes have hydrophobic outer shell 
(lipid bilayer) and internal hydrophilic compartments so that hydrophobic molecules such as drugs or 
macromolecules can be attached to the outer shell and hydrophilic molecules can be encapsulated into 
the inner aqueous space. There are many advantages such as versatility, biocompatibility, 
biodegradability, low toxicity and easy modification. In order to overcome the limitation of liposomes, 
after drugs are encapsulated into the liposomes, internal drugs are simply released by stimuli like 
temperature, pH or magnetism.  
 
1.2.3. Virus-like particles (VLPs) 
VLPs are called as viral capsid proteins due to lacking DNA or RNA genome of the virus. Viral 
particles have many properties such as nanometer size, robust protein shells, uniformity, and easy 
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bioconjugation and modification.[1] Among VLPs, cowpea mosaic virus (CPMV) is well known and 
researched. In common with protein cages, VLPs have a bigger hollow cavity which can encapsulate 
molecules such as small molecules, drugs and probes.  
 
1.2.4. Ferritin protein cages 
As a globular protein, a ferritin family protein consists of 24 subunits and has self-assembly system. 
24 identical subunits become self-assembled into a spherical cage which is symmetry. Ferritin protein 
has an outer diameter of 12 nm and inner diameter of 8 nm. It has a very uniform size and hollow 
form. Inner space can encapsulate small molecules via genetic and chemical modification. Also, 
external surface can be easily modified because the structure and sequence of ferritin proteins are 
widely known. Recently, many studies related to ferritin family protein have been reported.    
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Figure 1. The relative scale of biological molecules and structures. Cells can vary between 1 
micrometer (μm) and hundreds of micrometers in diameter. Within a cell, a DNA double helix is 
approximately 10 nanometers (nm) wide, whereas the cellular organelle called a nucleus that encloses 
this DNA can be approximately 1000 times bigger (about 10 μm). See how cells compare along a 
relative scale axis with other molecules, tissues, and biological structures (blue arrow at bottom). Note 
that a micrometer (μm) is also known as a micron. 
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Figure 2. Multifunctional nanoparticles for biomedical application. Particles in nanosize have 
significantly different characteristics from particles not in nanoscale. Since these nanoparticle 
properties are often in many applications, they have been applied in a wide variety of medical 
research. 
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General Chemistry: Principles, Patterns, and Applications, v. 1.0  
 
 
Figure 3. Polymer Formation. Polymers are very large molecules made when hundreds of monomers 
join together to form long chanins. The word ‘ polymer’ comes from the Greek words poly (meaning 
‘many’) and meros (meaning ‘parts’) 
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Figure 4. Liposomes are made of phospholipid molecules that spontaneously self-assemble into 
spherically closed bilayer membranes, where the polar heads are hydrated with water, whereas the 
hydrophobic hydrocarbonchains of each leaflet of the bilayer core interact with each other. The 
thickness of the lipid bilayer of the liposomes is typically about 5 nm. Typical phospholipids used to 
prepare liposomes include phosphatidyl cholines (PC), phosphatidyl ethanolamines (PE), and 
phosphatidyl glycerols (PG). In addition, other lipids are usually incorporated into liposomes such as 
cholesterol, phosphatidyl inositol (PI), phosphatidyl serine (PS), and sphingomylin. The phospholipid 
composition of liposomes defines membrane surface properties; for highly dependent on presence of 
charged lipids. 
 
 
 
 
17 
 
 
2016 VBI Vaccines Inc. | Disclaimer and Terms of Use 
 
 
Figure 5. eVLP Vaccine Components and Design. Virus-like particles (“VLPs”) are protein structures 
designed to mimic the organization and conformation of viruses as they occur in nature but without 
the viral genome, potentially yielding safer and more potent vaccine candidates. Unlike first-
generation and second-generation VLP approaches, which have yielded successful vaccines but can 
mean limited rational and flexible design potential, VBI’s eVLP Platform provides a stable foundation 
that mimics enveloped viruses and is suitable for a wide array of vaccine candidates.3 
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Figure 6. Ferritin representing the 24 subunits assembled to form the hollow spherical protein with a 
12 nm diameter exterior and an 8 nm diameter interior cavity with an encapsulated mineral. [8] 
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Figure 7. Library of protein cages. Protein cage nanoparticles are excellent candidates for use as 
multifunctional delivery nanoplatforms because they are built from biomaterials and have a well-
defined structure. 
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Figure 8. Materials scientists increasingly draw inspiration from the study of how biological systems 
fabricate materials under mild synthetic conditions by using self-assembled macromolecular templates. 
Containerlike protein architectures such as viral capsids and ferritin are examples of such biological 
templates. These protein cages have three distinct interfaces that can be synthetically exploited: the 
interior, the exterior, and the interface between subunits. The subunits that comprise the building 
blocks of these structures can be modified both chemically and genetically in order to impart designed 
functionality to different surfaces of the cage. [9] 
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Chapter 2. Polyvalent Display of Monosaccharides on Ferritin Protein 
Cage Nanoparticles for the Recognition and Binding of Cell-surface Lectins. 
 
2.1. Introduction 
Cell-surface lectins recognize and interact with specific carbohydrates and glycoconjugates, such as 
glycoproteins and glycolipids. These interactions play an important role in many biological events, 
such as cell–cell communication, cell signaling, cell adhesion, and viral and bacterial infections.[1, 2] 
Individual cells occasionally present specific lectins on their cell surface.[3] Thus, endogenous lectins 
are attractive markers for the recognition and targeting of specific cells to modulate cellular events 
and drug and/or gene delivery.[3-5] However, individual carbohydrate–lectin interactions are 
relatively weak, with association constants (Ka) of approximately 10
6
 M
−1
, because carbohydrate 
recognition domains (CRDs) contain shallow binding grooves that are largely exposed to solvents.[6, 
7] Nature solves this paradox by utilizing multimeric glycan display enhancing the specificity through 
avidity, so-called “cluster glycoside effect.”[8] The seminal works by the Lee group demonstrated that 
the number and branching mode of synthetic clustered glycan ligands are the major determinants for 
lectin binding.[8-10] A number of research groups have demonstrated that multivalent scaffolds, 
including dendritic structures, polymers, liposomes, and nanomaterials, can effectively inhibit the 
binding of various types of pathogens to the cell-surface lectins of a host organism.[6, 7, 11, 12] 
Recently, the Davis group conjugated mannose-terminated glycodendrons (1 620 copies of glycan) to 
the icosahedral bacteriophage Qβ to mimic a target pathogen, pseudo-typed Ebola virus.[13] The 
multivalent glycodendriproteins showed competitive binding to the dendritic cell-specific intercellular 
adhesion molecule-3-grabbing nonintegrin (DC-SIGN) receptor.[13-16] However, there have been 
few studies that utilized glycoconjugates as cell-surface lectin-targeting delivery vehicles.[17-19] For 
the development of efficient ligand-based probes and/or delivery vehicles that target cell-surface 
lectins, establishment of polyvalent nanoplatforms that are well defined and easy to manipulate and of 
simple methods to generate a variety of carbohydrate conjugates is necessary. In this study, we used 
human heavy-chain ferritin protein cage nanoparticles (HFPCNs) as well-defined polyvalent 
nanoplatforms. Two different types of monosaccharide (mannose or galactose)-derivatives were 
chemically synthesized and conjugated to a defined site on the HFPCNs through thiol-maleimide 
Michael-type addition (Scheme 1). Uniform and polyvalent displays of mannosyl or galactosyl units 
on the surface of HFPCNs were examined by size exclusion chromatography (SEC) and mass 
spectrometry (MS). The specific binding of monosaccharide-conjugated HFPCNs to their 
corresponding lectins was also investigated by surface plasmon resonance (SPR) measurements. 
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Using fluorescent cell imaging, we demonstrated the targeted delivery of monosaccharide-conjugated 
HFPCNs to mammalian cells that presented specific lectins on their surface. 
 
2.2. Material and Methods 
 
Mutagenesis and Purification of Human Heavy Chain Ferritin Protein Cage Nanoparticles 
(HFPCN) 
Escherichia coli (BL21 (DE3), Novagen) containing pET-30b HFPCN plasmids were grown 
overnight in LB medium with 30 mg L−1 kanamycin. Protein production was induced by IPTG (1 mM), 
and cells were incubated at 18 °C overnight. After the incubation, cells were collected by 
centrifugation and then the pellets were resuspended in lysis buffer (50 mM phosphate, 100 mM NaCl, 
pH 6.5) with lysozyme, DNAse, and RNAse. After 30 min incubation on ice, the solution was 
subjected to sonication on ice. The solution was centrifuged to remove E. coli debris and the 
supernatant was heated at 60 °C for 10 min, precipitating many of the E. coli proteins, which were 
removed by centrifugation. The supernatant was loaded onto a 10 mm ×  300 mm Superose 6 (GE 
Healthcare) size exclusion column and eluted with buffer containing 50 mM phosphate, 100 mM 
NaCl (pH 6.5) at a rate of 0.5 mL min−1.[20] 
 
Syntheses of AMM and AGM 
Mannosyl/galactosyl thiols 1,5 were synthesized from glycosyl bromides by thiourea treatment 
followed by mild hydrolysis.[21, 22] The thiosugars 1,5 were then treated with nitrobenzyl bromide in 
the presence of TEA to produce (p-nitrobenzyl)2,3,4,5-tetra-O-acetyl-1-thio-α-D-mannopyranoside (2) 
and (p-nitrobenzyl)2,3,4,5-tetra-O-acetyl-1-thio-β-D-galactopyranoside (6), respectively. The 
aromatic nitro groups were reduced using stannous chloride in absolute ethanol heated at 70 °C, to 
generate p-anilinyl-linked sugar derivatives 3, 7. The amine termini were treated with N-succinimidyl-
3-maleimido-propionoate,[20, 23] to generate maleimido group terminated per-acetylated-
mannopyranoside (AMM) 4 or maleimido group terminated per-acetylated-galactopyranoside (AGM) 
8 (see Supporting Information in detail). 
 
Surface Plasmon Resonance (SPR) Analysis 
In SPR experiments, carboxyl dextran CM-5 gold chips was used on a Biacore 3000 device (Biacore 
AB, Sweden) at 25 °C. For coupling on surface of sensor chip, HBS-EP buffer (GE Healthcare) was 
used as running buffer.[24] A mixture of EDC and NHS activated carboxyl groups on the sensor 
surface with flow rate of 10 mL min−1 and subsequently 10 μg mL−1 of each concanavalin A from 
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Canavalia ensiformis (ConA, Sigma) and lectin from Pseudomonas aeruginosa (PA-IL, Sigma) was 
immobilized on surface of sensor chip for mannose and galactose, respectively, at the same flow rate 
for 7 min. Excess activated carboxyl groups were blocked with 1 M ethanolamine (pH 8.0). To induce 
the interaction of carbohydrate and lectin, running buffer change to 10 mM HEPES (pH 7.4), 150 mM 
NaCl, 5 mM CaCl2, and 0.005% Tween 20. Concentrate gradient of each carbohydrate (3 μM, 0.6 μM, 
0.12 μM, 0.024 μM, and 0.0048 μM) were injected over the ligand immobilized surfaces at flow rate 
of 25 μL min−1 for 60 s. 
 
Cell Culture and Fluorescence Microscopy 
DCEK cells which over-express DC-SIGN on their surface stably were prepared as described 
previously[25] and HepG2 cells which over-express ASGP-R on their surface were purchased from 
the American Type Culture Collection (ATCC, Manassas, VA). DCEK cells and HepG2 cells were 
cultured in RPMI1640 medium with L-glutamine (300 mg L−1) contained with 5% v/v fetal bovine 
serum (FBS, Invitrogen Corp., Carlsbad, CA) and 1% antibiotic–antimycotic (Invitrogen Corp., 
Carlsbad, CA) at 37 °C under 5% CO2. Both cells (1 ×  10
5
/well) were grown in 12-well plate 
incorporating microscope cover glasses (Marienfild, Germany). The cells were fixed with 4% 
paraformaldehyde at room temperature for 10 min and washed three times with PBS containing 0.05% 
Tween 20. After blocking with 5% FBS, 5% BSA, and 0.5% Tween 20 in DPBS at 4 °C overnight, 
NHS-Fluorescein (Thermo Fisher Scientific, Inc., USA) conjugated Man- or Gal-HFPCN was treated 
to each cell in DPBS (GIBCO by life technologies, USA) and incubated at 4 °C for 12 h. Finally, the 
cells were washed three times with PBS containing 0.05% Tween 20. VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratoried, Inc., USA) were used to mount cells and stain DNA on 
slide. 
 
2.3. Results 
 
Human ferritin has been extensively used as a template for the synthesis of biomimetic nanomaterials 
and as a protein-based targeted-delivery nanoplatform in biomedical research.[26-31] To display 
monosaccharides on the surface of human ferritin in a controlled manner, we used previously 
generated HFPCNs, which have a single cysteine residue (C90) for every subunit on their surface (24 
cysteines per cage), as polyvalent nanoplatforms.[20] Previously, we demonstrated that these 
cysteines are exposed on the surface of the nanoplatforms and are therefore fully available for the 
attachment of functional moieties.[20] To display monosaccharides on the surface of HFPCN in a 
controlled manner, maleimido-linked carbohydrate derivatives were prepared as described in 
Experimental Section (Scheme 2). Because acetyl groups, which protect the hydroxyl groups of 
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monosaccharide derivatives, can be easily cleaved by raising the pH to 11,[32] HFPCNs were first 
treated with either AMM or AGM, and the reaction mixtures were subsequently dialyzed overnight at 
pH 11 for the conversion of the acetyl groups to hydroxyl groups. The reactions were then neutralized, 
pending further analysis. To determine the extent of AMM or AGM functionalization on the surface 
of the HFPCNs, and the degrees of deacetylation of the AMM- or AGM-modified HFPCNs, we 
performed molecular mass analyses of the modified HFPCN subunits by using electrospray 
ionization-time of flight MS (ESI-TOF MS).[33, 34] The molecular masses of the HFPCN subunits 
that were treated with either AMM or AGM were the same (21 683.0 Da). This is in excellent 
agreement with the calculated value corresponding to one AMM- or AGM-conjugated HFPCN 
subunit (21 682.5 Da, Figure 1A and Supporting Information, Figure S1A), because both mannose 
and galactose have the same chemical composition with different configuration. These data suggest 
that each subunit of the HFPCN was modified with only one AMM or AGM, without any side 
reaction. As a result, each HFPCN had 24 AMMs or AGMs per cage. To transform acetyl groups into 
hydroxyl groups, AMM- or AGM-conjugated HFPCNs were dialyzed at pH 11. The HFPCNs 
maintained their structural integrity at pH 7 and 11, and showed no sign of aggregation or dissociation 
of cage assembles in response to shifts in pH (data not shown). The reactions were sampled at various 
time points and the molecular masses of the modified HFPCN subunits were determined by ESI-MS 
to confirm the completion of deacetylation (Supporting Information, Figure S2). All four hydroxyl 
(OH) groups of Man or Gal are protected with acetyl groups in AMM or AGM and one conversion of 
each acetyl group to hydroxyl group supposedly results in mass decrease of 42 Da. The molecular 
mass measurements revealed that the mass of the modified HFPCNs gradually decreased (multiple of 
42 Da) as the pH increased. The deacetylation was completed almost 15 h after the start of the 
reaction (Supporting Information, Figure S2) resulting in a final molecular mass value of 21 533.0 Da, 
which is slightly higher than the expected mass value (21 514.5 Da) owing to the oxidation of 
thioether to the sulfoxide within the linker, as reported previously[35] (Figure 1B and Supporting 
Information, Figure S1B). We incubated AMM- or AGM-conjugated HFPCNs at pH 11 for 15 h and 
subsequently neutralized them to obtain mannose-conjugated HFPCNs (Man-HFPCNs) or galactose-
conjugated HFPCNs (Gal-HFPCNs), and used these for further analyses. The Man- or Gal-HFPCNs 
formed were eluted at the same position as untreated HFPCNs on SEC, and high absorption ratios 
were observed between 260 and 280 nm, probably due to the presence of a phenyl ring in the linker 
between the monosaccharides and HFPCNs (Figure 1C and Supporting Information, Figure S1C). 
Transmission electron micrographs of negatively stained Man- or Gal-HFPCNs exhibited an intact 
cage-like structure with an outer diameter of approximately 13 nm (Figure 1D and Supporting 
Information, Figure S1D). These data suggest that mannosyl or galactosyl moieties were covalently 
attached to the surface of HFPCNs and that HFPCNs remain intact upon conjugation and 
deacetylation (pH shifts) (Figure 1 and Supporting Information, Figure S1). A variety of glycan 
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structures on the surfaces of cells and bacteria are able to recognize and interact with cell-specific 
lectins. To investigate whether Man- or Gal-HFPCNs recognize and interact with specific lectins, we 
performed SPR analyses.[24] SPR CM-5 sensor chips were first immobilized individually with C. 
ensiformis concanavalin A (ConA) or P. aeruginosa lectin (PA-IL) to form a lectin layer on the 
surface of sensor chips because ConA and PA-IL have been known to specifically recognize and bind 
to the terminal mannosyl and galactosyl moieties, respectively.[1, 5, 36] The corresponding Man-
HFPCNs or Gal-HFPCNs were then applied to the ConA or PA-IL immobilized SPR CM-5 sensor 
chips, respectively, at various concentrations (Figure 2A,C). AMM-HFPCNs and AGM-HFPCNs 
were used in parallel as negative controls because they do not bind to the lectins owing to the 
complete acetylation of the hydroxyl groups of their monosaccharide moieties (Figure 2B,D). While 
gradual increases in SPR response units (RU) were observed upon the introduction of Man-HFPCNs 
or Gal-HFPCNs to ConA or PA-IL immobilized SPR CM-5 sensor chips (Figure 2A,C), no RU 
change was observed with AMM-HFPCNs and AGM-HFPCNs (Figure 2B,D). These data suggest 
that the monosaccharides displayed on the surface of HFPCNs recognized specific lectins 
(mannose/ConA and galactose/PA-IL) and bound to their specific lectin partners. Furthermore, slight 
or no apparent dissociations of Man-HFPCNs or Gal-HFPCNs from ConA or PA-IL immobilized 
SPR CM-5 sensor chips were observed even after extensive washing with buffer (Figure 2), implying 
that the polyvalent presentation of monosaccharides on the surface of HFPCNs caused them to 
cooperatively interact with immobilized lectins, resulting in strong association.[24, 37-39] Although 
we could not determine accurate dissociation constants of Man-HFPCNs or Gal-HFPCNs toward 
ConA or PA-IL, we could briefly estimate association rate constants (ka values for Man-HFPCNs and 
Gal-HFPCNs were 3.8 ×  105 and 9.03 ×  104, respectively) comparable with previous studies[17-19] 
(Supporting Information, Table S1). These data suggest that HFPCNs can serve as versatile 
nanoplatforms for presenting different types of carbohydrates that can be attached to them on demand, 
by using simple bioconjugation. Endogenous lectins are potential targets for manipulating cell–cell 
communications and immune responses as well as attractive targets for drug and/or gene delivery to 
specific target cells.[3-5] To demonstrate the targeted delivery of Man-HFPCNs and Gal-HFPCNs to 
specific mammalian cells, we chose DC-SIGN and asialoglycoprotein receptor (ASGP-R), 
respectively, as target cell-surface lectins. DC-SIGN is a C-type lectin, which is expressed on the 
surface of dendritic cells (DCs) and is able to recognize specific carbohydrate structures, such as 
mannose- and fucose-containing glycoproteins.[4, 40] It acts as a pattern recognition receptor that 
induces specific immune responses upon interaction with numerous pathogens, as well as a site that 
binds to surface carbohydrates of lethal opportunistic pathogens, such as HIV-1 and Mycobacterium 
tuberculosis.[40] ASGP-R is a particularly attractive target for effective drug and gene delivery to the 
liver because it is predominantly expressed on the surface of hepatocytes, recognizes specific ligands 
with a terminal galactose, and is involved in receptor-mediated endocytosis.[41] To investigate the 
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potential use of Man-HFPCNs and Gal-HFPCNs as lectin-targeted delivery nanocarriers, we further 
labeled Man-HFPCNs and Gal-HFPCNs with N-hydroxysuccinimide (NHS)-ester-fluorescein (fMan-
HFPCNs and fGal-HFPCNs, respectively, Supporting Information, Figure S3), and prepared DCEK 
(mouse L-cell fibroblast line) cells, which stably overexpress DC-SIGN on their surface,[25] and 
HepG2 cells, which overexpress ASGP-R on their surface.[42] The DCEK or HepG2 cells were 
treated with fMan-HFPCNs or fGal-HFPCNs and visualized by fluorescence microscopy to examine 
lectin-specific binding of monosaccharide-conjugated HFPCNs. AMM-HFPCNs and AGM-HFPCNs 
were also labeled with NHS-ester-fluorescein (fAMM-HFPCNs and fAGM-HFPCNs, respectively) 
and used as negative controls. While neither fAMM-HFPCNs nor fAGM-HFPCNs bound to DCEK or 
HepG2 cells (Figure 3A,B, tops), fMan-HFPCNs and fGal-HFPCNs specifically bound to DCEK and 
HepG2 cells, respectively (Figure 3A,B, bottoms). These data suggest that the multiple mannoses or 
galactoses that were presented on the surface of the HFPCNs allowed them to recognize and strongly 
bind to specific lectins on the mammalian cells. 
 
2.4. Conclusion and discussion 
 
We prepared HFPCNs that had multiple cysteine residues at defined positions on their surface, and 
two different types of monosaccharide derivatives; AMM and AGM. Uniform and polyvalent displays 
of mannoses or galactoses on the surface of HFPCNs were produced and the specific binding of 
mannose-displaying HFPCNs (Man-HFPCNs) or galactose-displaying HFPCNs (Gal-HFPCNs) to 
their corresponding model lectins, ConA or PA-IL, respectively, was confirmed by using SPR 
analyses. The polyvalent presentation of monosaccharides on the HFPCN surface resulted in a strong 
association with the target lectins. The targeted delivery of Man-HFPCNs or Gal-HFPCNs to the 
mammalian cells, DCEK or HepG2 cells, which overexpressed DC-SIGN or ASGP-R lectins on the 
surface, was demonstrated using fluorescent cell imaging. In addition to their exterior surface, 
HFPCNs have an additional space, the interior cavity, which can be used to encapsulate functional 
nanomaterials and/or attach cargo molecules such as imaging probes and therapeutic drugs.[43, 44] 
When combined with interior modifications, the targeting capability of monosaccharide-displaying 
HFPCNs to specific cell-surface lectins will provide opportunities for developing finely tuned 
multifunctional protein cage-based drug or/and diagnostic delivery nanoplatforms. 
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Scheme 1. Polyvalent display of monosaccharides on HFPCNs through thiol-maleimide Michael-type 
addition in a controlled manner and the selective binding of monosaccharide-conjugated HFPCNs to 
cell surface lectins. 
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Scheme 2. Synthesis of mannose and galactose derivatives for the synthetic glycoprotein formation: 
A) 4-nitrobenzyl bromide, DMF, TEA, r.t., Man 81%, Gal 90%; B) SnCl2–2H2O, EtOH, 70 °C, Man 
44%, Gal 50%; C) N-succinimidyl 3-maleimido-propionoate, DMF/(DCM), DIPEA, Man 73%, Gal 
52%. DMF, N,N-dimethylformamide; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; 
TEA, triethylamine. NMR spectra of synthetic intermediates and products were recorded (Supporting 
Information, Figure S4–S9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
 
Figure 1. Molecular mass measurements of dissociated subunits of (A) AMM-HFPCN (calcd., 
21 682.5 Da, obs, 21 683.0 Da) and B) Man-HFPCNs (calcd., 21 514.5 Da, obs, 21 533.0 Da). C) Size 
exclusion elution profiles (black line: 280 nm, red line: 260 nm) of AMM-HFPCN (top) and untreated 
HFPCN (bottom). D) Transmission electron microscopic (TEM) image of 2% uranyl acetate stained 
Man-HFPCN. TEM image confirmed an intact cage architecture of Man-HFPCN with a uniform size 
distribution. 
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Figure 2. SPR analyses of A) Man-HFPCN and C) Gal-HFPCN binding to Con A and PA-IL 
immobilized CM-5 sensor chips. SPR responses (RU) were gradually increased upon the introduction 
of Man-HFPCN or Gal-HFPCN at various concentrations. No apparent RU changes were observed 
with B) AMM-HFPCN and D) AGM-HFPCN whose hydroxyl groups are completely acetylated. 
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Figure 3. Fluorescent microscopic images of A) DCEK cells and B) HepG2 cells treated with fMal-
HFPCN (A, left, bottom) and fGal-HFPCN (B, left, bottom) or fAMM-HFPCN (A, left, top), and 
fAGM-HFPCN (B, left, top). Nucleus was stained with DAPI (A, B, right top and bottom). 
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Figure S1. Molecular mass measurements of dissociated subunits of (A) AGM-HFPCN (calc, 
21682.5 Da; obs, 21683.5 Da) and (b) Gal-HFPCNs (calc, 21514.5 Da; obs, 21533.0 Da). Size 
exclusion elution profiles (black line: 280 nm, red line: 260nm) of AGM-HFPCN (C,top) and 
untreated HFPCN (C, bottom). The samples were loaded onto a 10 x 300 mm superpose 6 size 
exclusion column, which had been pre-equilibrated with 50 mM phosphate and 100 mM NaCl (pH 6.5) 
and then eluted with the same buffer at a rate of 0.5 mL/min. Transmission electron micrographic 
(TEM) image of 2 % uranyl acetate stained Gal-HFPCN. TEM image confirmed an intact cage 
architecture of Gal-HFPCN with a uniform size distribution.   
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Figure S2. Molecular mass measurements of dissociated subunits of (A) AMM-HFPCN and (C) 
AGM-HFPCN incubated at pH 11 for 0,1,6,15,24, and 48 hr (bottom to top). The mass of the 
modified HFPCNs gradually decreased (multiple of 42 Da) as the incubation time increased at pH 11. 
No apparent change was observed with (C) AMM-HFPCN and (D) AGM-HFPCN incubated at pH 7 
up to 24hr. Observed masses were listed a s a separate table.   
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Figure S3. Molecular mass measurements of (A) Mal-HFPCN and (B) Gal-HFPCN treated with N-
hydroxysuccinimide (NHS)-ester-fluorescein. Approximately 40% of Mal-HFPCN subunits and 50 % 
of Gal-HFPCN subunits were modified with one fluorescein (*), respectively.  
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Chapter 3. Developing an Antibody-binding Protein Cage as a Molecular 
Recognition Drug Modular Nanoplatform 
 
3.1. Introduction 
 
Remarkable developments have been achieved in the field of drug discovery and biomedical 
diagnostics techniques. However, there are still tremendous demands for early detection and localized 
treatment of diseases, such as cancers, and reduction of side effects of therapeutics. Development and 
usage of efficient delivery vehicles is one of the promising approaches for early diagnostics of 
diseases and the effective drug administration. Delivery systems of therapeutics and diagnostics have 
evolved from passive delivery, which primarily relies on enhanced permeability and retention (EPR) 
of particles and molecules in tumor tissues, to active targeted delivery, of which targeting capability is 
dependent on targeting molecules specific to the targets, thus maximizing diagnostic signal and drug 
efficacy [1], [2], [3] and [4]. The delivery platforms studied extensively include liposomes [5], 
[6] and [7], block copolymers [8], [9], [10] and [11], dendrimers [12] and [13], inorganic 
nanoparticles [14], [15], [16], [17] and [18], and protein cage architectures [19], [20], [21], [22], [23], 
[24], [25] and [26]. These systems often utilize targeting moieties, such as chemical ligands, peptides, 
and antibodies, to enhance their efficiency of delivery [2], [3] and [4]. Antibodies are the preferred 
targeting moieties due to their high selectivity, affinity and variability to their targets [19], [27], 
[28] and [29]. Conventionally, antibodies are directly cross-linked chemically to the surface of 
delivery platforms or both the antibodies and platforms can be chemically modified, followed by 
mediator-assisted complex formation, such as biotin–streptavidin interactions [19], [27], [30], [31], 
[32], [33] and [34]. Although several methods have been used to selectively conjugate antibodies to 
delivery platforms [19], [27], [30], [31], [32], [33] and [34], chemical conjugations and related 
approaches often impair the binding capability of antibodies due to alterations in their antigen binding 
sites, denaturation, or random orientation of the antibodies [33]. Therefore, more effective methods 
are necessary to couple antibodies and delivery platforms without altering the targeting capability of 
displayed antibodies. Antibody-binding proteins, such as protein A, G, and L, and their derivatives are 
widely used for purifying antibodies [33] and [35]. These proteins non-covalently capture antibodies 
by specifically binding to the fragment crystallizable region (Fc) of antibodies, thereby captured 
antibodies fully retain their structure and function [33] and [35]. Although these proteins have been 
well-characterized and widely used for capturing antibodies, their large size and long-term instability 
limited their application for antibody immobilization. Recently, small peptides mimicking antibody-
binding proteins have been screened and identified by phage display technique [36]. Its Fc-binding 
ability was confirmed by X-ray crystallographic analysis of the peptide–antibody complex. We 
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recently described the successful use of the Fc-binding peptide (FcBP) of human IgG for orientation-
controlled antibody immobilization on sensor chips via molecular recognition [37]. Small binding 
peptides are generally stable and easy to genetically incorporate into the protein-based nanoplatforms. 
Protein cages, including ferritins, viral capsids, and heat shock proteins, are attractive candidates for 
nano-scale cargo delivery vehicles. While the interior surfaces of the protein cages have been used for 
encapsulation, attachment and synthesis of organic and inorganic materials, their exterior surfaces 
have been used for multivalent presentations of molecules, including affinity tags, antibodies, 
fluorophores, carbohydrates, nucleic acids, and peptides, for molecular targeting and hierarchical 
structure formation [20], [21], [22], [23], [24], [25] and [26]. As a model nano-scale delivery platform, 
we used ferritin (Pf_Fn) protein cage isolated from the hyperthermophilic archaeon, Pyrococcus 
furiosus, living optimally at 100 °C. [38]. Each Pf_Fn protein cage consists of 24 identical 20 kDa 
subunits, which self-assemble into a spherical cage with inner and outer diameters of 8 and 12 nm, 
respectively (Fig. 1A) [38]. Each subunit has a 4 helix bundle (helices A–D) and a tilted fifth short α-
helix (helix E), connected by a flexible loop region (Fig. 1A). When they assemble to form a spherical 
cage, four flexible loops from four subunits form a cluster at the surface of the four fold symmetry 
axis. 
 
3.2. Material and Methods 
 
FcBP insertion and protein cage purification 
The residues GGGGGGDCAWHLGELVWCTGGGGGAS were inserted into the 146 position of wt 
Pf_Fn by an established PCR protocol, using primers containing extra nucleotides and pET-30b based 
plasmids containing genes encoding Pf_Fn protein as a template. The amplified DNAs were used to 
transform the competent Escherichia. coli strain BL21 (DE), resulting in the over-expression in 
E. coli of the Pf_Fn protein cage containing inserted FcBP. The resultant protein was purified as 
described previously [39] 
 
Quartz crystal microbalance (QCM) measurements 
QCM experiments were performed using Q-Sense E4 and standard gold QCM sensors (Q-Sense, 
Sweden) as described previously, with slight modifications [39]. Briefly, the system was operated in 
flow mode with a pump and temperature was maintained at 25.0 ± 0.1 °C. Each sample solution was 
introduced to the measurement chamber with a pump and continuously measured for 3 min prior to 
the subsequent introductions. Various Pf_Fn protein cages and human or rabbit IgG were introduced 
at concentrations of approximately 100 μg/ml and 50 μg/ml, respectively, in phosphate buffer (50 mM 
phosphate, 100 mM NaCl, pH 6.5). Resonance frequencies were measured simultaneously at seven 
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harmonics (5, 15, 25, 35, 45, 55 and 65 MHz). For clarity, only the normalized frequency of the third 
overtone is shown.. 
 
Surface plasmon resonance (SPR) analysis 
SPR experiments were performed with carboxyl dextran CM-5 gold chips on a Biacore 3000 device 
(Biacore AB, Sweden) at 25 °C using a PBS buffer as a running solution. Human or rabbit IgG was 
coupled to the surface of a CM-5 sensor chip by standard amine-coupling chemistry on the SPR 
instrument as described previously, with slight modifications [40]. Briefly, a mixture of EDC (0.4 M) 
and NHS (0.6 M) was injected onto the chip at a flow rate of 10 μl/min to activate carboxyl groups on 
the sensor surface and subsequently 20 μg/ml of human or rabbit IgG was added at the same flow rate 
for 7 min. Excess reactive groups were blocked with 1 M ethanolamine (pH 8.0). FcBP-Pf_Fn capture 
by human IgG or rabbit IgG was examined by applying various amounts (1, 5, 10, 25, 50, and 100 nM) 
of FcBP-Pf_Fn (PBS, pH 7.4) to the surface at a flow rate of 30 μl/min. 
 
Cell culture 
SKBR3 and MCF10A were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA). SKBR3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% (v/v) fetal bovine serum (FBS, Invitrogen Corp., Carlsbad, CA) and antibiotics (100 μg/mL 
penicillin and 50 μg/mL streptomycin) at 37 °C under 5% CO2. MCF-10A cells were cultured in 
DMEM F12 medium, supplemented with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin 
(10 μg/mL), hEGF (20 ng/mL) and antibiotics (100 μg/mL penicillin and 50 μg/mL streptomycin). 
KB cells, obtained from the Korean cell line bank (KCLB), were cultured in RPMI1640 medium with 
l-glutamine (300 mg/L), 10% FBS, 25 mM HEPES and 25 mM NaHCO3. 
 
Preparation and analysis of fluorescence microscopy samples 
MCF-10A and SKBR3 cells (2×10
4
/well) were grown in 8-well microscopy chambers (Ibidi GmbH, 
Martinsried, Germany). fFcBP-Pf_Fn (final 50 nM), Cy3-trastuzumab (final 200 nM) and rabbit IgG 
(final 100 nM) were mixed in DMEM supplemented with 10% (v/v) FBS, antibiotics, and 0.05% 
Tween 20, and incubated at room temperature for 30 min. A mixture of fFcBP-Pf_Fn and Cy3-
trastuzumab was added to each well and incubated at 37 °C for 30 min. The cells were washed three 
times with PBS containing 0.05% Tween 20, and fixed with 4% paraformaldehyde at room 
temperature for 20 min, and again washed with PBS. The cells were incubated with 4′,6-diamidino-2-
phenylindole (DAPI, Sigma) in PBS for 10 min and washed with PBS. Fluorescence images are 
obtained using a Personal DV microscope (Applied Precision, Washington, USA). 
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3.3. Results 
 
Construction of FcBP-presenting Pf_Fn protein cages 
To adapt Pf_Fn protein cage as a nanoplatform for displaying antibodies in an orientation-controlled 
manner, we genetically introduced a small FcBP (DCAWHLGELVWCT), which has a high affinity 
to both human (Kd = 85 nM) and rabbit (Kd = 305 nM) IgGs [37], into the loop region connecting 
helices D and E (Fig. 1A). The loop regions are exposed on the surface of the Pf_Fn protein cages, 
allowing the inserted FcBP moieties to easily form intra-strand disulfide bonds due to their proximal 
distant induced by the loop configuration (Fig. 1A) [38]. These moieties cluster around the four-fold 
axis of symmetry, which may result in cooperative binding of the Fc regions of the target antibodies 
(Fig. 1A). Extra glycine residues were added to both sides of each FcBP to enhance their 
conformational flexibility and to provide full access to approaching antibodies (Fig. 1A). FcBP 
insertion was confirmed by DNA sequencing and molecular mass measurement of subunit of FcBP 
inserted Pf_Fn protein cages (FcBP-Pf_Fn). FcBP-Pf_Fn was over-expressed in E. coli as a soluble 
protein without noticeable amounts of precipitation. FcBP-Pf_Fn was purified by the same method 
used to purify wild type Pf_Fn protein cages (wt Pf_Fn) [39], resulting in similar yields of FcBP-
Pf_Fn and wt Pf_Fn (∼10 mg/L culture). Purified FcBP-Pf_Fn was characterized by size exclusion 
chromatography (SEC), transmission electron microscopy (TEM), dynamic light scattering (DLS), 
and mass spectrometry (MS) and compared with wt Pf_Fn. FcBP-Pf_Fn eluted at the same position as 
wt Pf_Fn on SEC, suggesting that FcBP-Pf_Fn forms a stable 24-mer cage architecture (Fig. 2A). 
TEM images of stained FcBP-Pf_Fn protein cages confirmed an intact cage architecture with a 
uniform size distribution (Fig. 2B), and DLS measurements of FcBP-Pf_Fn validated a hydrodynamic 
diameter of 13.2 nm, slightly larger than that of wt Pf_Fn (12 nm) probably due to the insertion of 
FcBP (Fig. 2C). Each FcBP-Pf_Fn subunit had a molecular mass of 22,600.0 Da, almost identical to 
the predicted molecular mass of 22,600.7 Da (Supporting Figure S1). These results indicate that 
FcBP-Pf_Fn forms an intact protein cage architecture without significant changes in size, composition, 
and architecture. 
 
Non-covalent association of FcBP-Pf_Fn and human antibodies driven by simple molecular 
recognition. 
It has been known that a synthetic FcBP (DCAWHLGELVWCT) has a high affinity to human IgGs 
with the value of Kd = 85 nM. [37]. We utilized real-time QCM to test whether FcBP-Pf_Fn has the 
binding capability to human IgGs as does synthetic FcBP itself. Typically, deposition of molecules on 
the QCM sensor results in decreases in resonance frequency (-ΔF) which are sensitive to the masses 
of the deposited molecules [39] and [41]. We have shown that protein cages that include ferritins and 
Dps (DNA binding protein from starved cells) strongly bind to the gold QCM sensor and form 
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uniform monolayers without any surface modifications [39] and [41]. The resonance frequency value 
of FcBP-Pf_Fn was lower than that of wt Pf_Fn, suggesting that the mass in the cages had increased 
due to the FcBP insertions (25 amino acids, an approximate 10% increase in mass) (Fig. 3A and 
Figure S2). The resonance frequency of each sample decreased, plateauing when it reached a certain 
value. In addition, no additional changes were observed even with continuous introduction of further 
sample, indicating that the Pf_Fn had formed a uniform monolayer regardless of whether FcBP had 
been inserted (Fig. 3A and Figure S2). To ensure that the surface of the QCM sensor was completely 
covered and that a stable monolayer had formed, the excess amounts of samples were introduced until 
the resonance frequency of each sample plateaued. Buffer was then allowed to flow over the QCM 
sensors to remove any unbound or loosely bound material. After a stable monolayer of wt or FcBP-
Pf_Fn had formed, we introduced human IgG solution over the monolayered QCM sensors and 
monitored frequency changes in real-time (Fig. 3A). While the frequency of FcBP-Pf_Fn-
monolayered QCM sensor decreased dramatically upon introduction of human IgG, the frequency of 
wt Pf_Fn-monolayered QCM sensor remained unchanged (Fig. 3A). Extensive washing removed only 
slight amounts of non-specifically associated human IgG with most of the initially bound human IgG 
remaining bound even after washing for 2 h (Fig. 3A). These findings indicated that human IgG binds 
strongly to FcBP-Pf_Fn but not to wt Pf_Fn, suggesting that human IgG binding was driven by the 
inserted FcBP. To evaluate whether further chemical modifications of FcBP-Pf_Fn alter its surface 
properties and antibody-binding capability, we labeled FcBP-Pf_Fn with fluorescein-5-maleimide and 
performed QCM experiments. Starting Pf_Fn has one cysteine per subunit on the exterior surface of 
the cage and this cysteine has been known to be easily labeled with cysteine reactive maleimide 
derivatives [39]. Fluorescein labeling of FcBP-Pf_Fn did not change the integrity or architecture of 
the protein cages (Figure S3). Subsequent QCM studies revealed that the binding patterns of 
fluorescein-labeled FcBP-Pf_Fn (fFcBP-Pf_Fn) to the surface of the gold QCM sensor and human 
IgG were almost identical to those of unlabeled FcBP-Pf_Fn, indicating that the surface properties of 
FcBP-Pf_Fn had been preserved, allowing them to bind to human IgG even after fluorophore 
conjugation (Figure S4). This result implies that FcBP-Pf_Fn can serve as a versatile nanoplatform 
which can address multiple functionalities on demand without losing targeting capability. To further 
investigate the binding affinity between FcBP-Pf_Fn and human IgG, we performed surface plasmon 
resonance (SPR) analysis. In contrast to QCM studies, human IgG was first immobilized on the 
surface of an SPR CM-5 sensor chip [37], followed by application of FcBP-Pf_Fn at several 
concentrations. Each experiment was performed after regeneration of free human IgG surface by 
base-washing of the FcBP-Pf_Fn bound to the IgG on the chip and subsequent equilibration with the 
appropriate binding buffer. Gradual increases in SPR responses (RU) were observed upon 
introduction of FcBP-Pf_Fn, with RU values reaching a plateau at each concentration (Fig. 3B). 
Consistent with previous QCM results, apparent dissociation of FcBP-Pf_Fn from the immobilized 
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human IgG was not observed even after extensive buffer washing (Fig. 3B). Furthermore, subsequent 
introduction of synthetic FcBPs did not disrupt the interaction between human IgG and FcBP-Pf_Fn, 
suggesting that the interaction between IgG and FcBP-Pf_Fn is much stronger than that of human IgG 
and synthetic FcBP (Kd = 85 nM) (Figure S5). These results indicate that multiple FcBPs at the four-
fold axis of FcBP-Pf_Fn may cooperatively capture IgGs and that these cooperative interactions are 
too strong to be broken, similar to biotin–streptavidin interactions (Fig. 3B). 
 
Specific binding of human antibody/FcBP-Pf_Fn complexes to the target cells.  
To demonstrate specific binding of non-covalent complexes of FcBP-Pf_Fn and human antibody to 
the target cells, we chose trastuzumab as a model human antibody. Trastuzumab is a monoclonal 
human antibody that binds selectively to the receptor HER2, which is over-expressed on the surface 
of breast cancer cells, and has been approved by the FDA to treat patients with HER2 positive breast 
cancer [42], [43] and [44]. To examine co-localization of antibodies and FcBP-PfFn, trastuzumab was 
labeled with Cy3 (Cy3-trastuzumab) and subsequently mixed with previously prepared fFcBP-Pf_Fn 
(Figure S3 and S4) to form Cy3-trastuzumab/fFcBP-Pf_Fn complexes. These complexes were 
subsequently incubated with SKBR3 breast cancer cells, which express high levels of HER2, and 
MCF10A breast cells, which lack HER2 expression, in the presence of excess amounts of rabbit 
serum and were visualized by fluorescence microscopy (Fig. 4). While neither Cy3-
trastuzumab/fFcBP-Pf_Fn complexes nor Cy3-trastuzumab itself bound to MCF10A cells (Fig. 4d–F), 
Cy3-trastuzumab/fFcBP-Pf_Fn complexes specifically bound to SKBR3 breast cancer cells (Fig. 4A–
C). Fluorescence images of Cy3-trastuzumab (Fig. 4A, orange) and fFcBP-Pf_Fn (Fig. 4B, green) 
corresponded well with each other, and merging of images confirmed the co-localization of Cy3-
trastuzumab and fFcBP-Pf_Fn (Fig. 4C). These data demonstrate that Cy3-trastuzumab/fFcBP-Pf_Fn 
complexes bind efficiently and specifically to HER2 expressed on the surface of SKBR3 breast cancer 
cells implying these complexes can be used as target specific molecular imaging probes. Although 
rabbit IgG has been known to bind FcBP and Cy3-Herceptin/fFcBP-Pf_Fn complexes were exposed 
to a large amount of components in rabbit serum, the binding of Cy3-Herceptin/fFcBP-Pf_Fn 
complexes to SKBR3 breast cancer cells was not inhibited (Fig. 4A–C). These results imply that the 
interactions between human IgG and fFcBP-Pf_Fn are too strong to be exchanged or interupted by 
rabbit IgG and other components in the serum during the time period used in this experiment. These 
complexes, remained intact in such a complex environment, have a potential to be used as an efficeint 
molecular imaging probe or a delivery vehicle both in vivo and in vitro. 
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Displaying rabbit antibodies on the modular nanoplatform, FcBP-Pf_Fn 
Rabbit IgG also showed a relatively high affinity to a synthetic FcBP, although its dissociation 
constant (Kd = 305 nM) is higher than that of human antibody (Kd = 85 nM) [37]. To test whether 
FcBP-Pf_Fn can serve as a modular delivery nanoplatform to display various types of targeting 
antibodies (IgGs) on the surface in an orientation-controlled manner, we attempted to construct the 
non-covalent complexes of rabbit IgG and FcBP-Pf_Fn and use them as probes for cell imaging. 
QCM and SPR studies were performed under the same condition as those of human IgG to validate 
the binding capability of FcBP-Pf_Fn to rabbit IgG. The binding patterns of rabbit IgG to the 
monolayered FcBP-Pf_Fn on the QCM sensor were almost identical to those of human antibody 
(Fig. 5A) suggesting rabbit IgG also binds strongly to FcBP-Pf_Fn but not to wt Pf_Fn as human IgG 
does. For SPR experiments, rabbit IgG was immobilized on the surface of an SPR CM-5 sensor chip 
instead of human IgG, [37], followed by application of FcBP-Pf_Fn at a series of concentrations. 
Gradual increases in SPR responses were observed upon introduction of FcBP-Pf_Fn, with RU values 
reaching a plateau at each concentration (Fig. 5B). Same as those of human IgG, apparent dissociation 
of FcBP-Pf_Fn from the immobilized rabbit IgG was not observed even after extensive buffer 
washing (Fig. 5B). These results confirmed that FcBP-Pf_Fn can form stable non-covalent complexes 
with rabbit IgG as well as human IgG. To demonstrate specific binding of non-covalent complexes of 
FcBP-Pf_Fn and rabbit antibody to the target cells, we chose rabbit anti-folate receptor antibody as a 
model rabbit antibody. To test tolerance of chemical modifications of FcBP-Pf_Fn with various types 
of fluorophores, FcBP-Pf_Fn was labeled with Alexa 647 (AlexaFcBP-Pf_Fn) and incubated with 
rabbit anti-folate receptor antibodies (RAnti-folateR-Ab) labeled with fluorescein (fRAnti-folateR-
Ab). Labeling did not significantly alter the stability of these molecules or their ability to form 
complexes. The resulting fRAnti-folateR-Ab/AlexaFcBP-Pf_Fn complexes were incubated with KB 
cells, which over-express folate receptors on their surface, and cells were examined by fluorescence 
microscopy (Fig. 6). While AlexaFcBP-Pf_Fn alone did not bind to KB cells (Fig. 6D, E), the fRAnti-
folateR-Ab/AlexaFcBP-Pf_Fn complexes bound specifically to KB cells (Fig. 6A–C). Fluorescence 
images of fRAnti-folateR-Ab (Fig. 6A, green) and AlexaFcBP-Pf_Fn (Fig. 6B, red) corresponded 
well with each other, and the merged image confirmed the co-localization of fRAnti-folateR-Ab and 
AlexaFcBP-Pf_Fn (Fig. 6C). These data demonstrate that the fRAnti-folateR-Ab/AlexaFcBP-Pf_Fn 
complexes bind efficiently and specifically to folate receptors over-expressed on the surface of KB 
cells. Together, these results indicate that FcBP-Pf_Fn can serve as a modular delivery nanoplatform 
for efficiently displaying a variety of human and rabbit antibodies on demand by simple molecular 
recognition. To our knowledge, this study is the first to show the successful construction of targeted 
delivery systems through the non-covalent association of antibodies with a protein cage by simple 
molecular recognition and the first to show the use of these systems as target specific imaging probes. 
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Depending on the target, this “mixing-and-matching” approach will allow these complexes to be used 
as versatile targeted delivery nanoplatforms. Antibodies offer an almost unlimited range of specific 
targeting moieties, making them attractive targeting ligands for effective targeted drug delivery and/or 
diagnostic systems [27], [28] and [29]. The approaches we described here overcome the drawbacks 
associated with chemical conjugation of antibodies. These engineered protein cages may constitute a 
modular unit that can bind a variety of targeting antibodies through molecular recognition, resulting in 
a delivery vehicle that actively targets tissues or cells that express the antigen targeted by the antibody. 
Since the fluorescent labeling on FcBP-Pf_Fn can be easily replaced by other imaging probes, 
including those for PET, MRI, and/or drugs, and FcBP-Pf_Fn has additional sites available for 
addressing functional activity or cargo transport into the system [20], [21], [22], [23], [24], 
[25] and [26], FcBP-Pf_Fn may offer a new paradigm for antibody-based targeted delivery. 
 
3.4. Conclusion and Discussion 
 
In this work, we have developed a protein cage-based delivery nanoplatform, FcBP-Pf_Fn, which can 
self-assemble with antibodies without chemical modification and serve as a versatile delivery 
nanoplatform. FcBP-Pf_Fn was prepared by genetically inserting FcBP into the flexible loop region 
of Pf_Fn and four FcBPs at a four-fold axis of symmetry formed an Fc-binding cluster on the cage 
surface exposing Fc-binding clusters to a human or rabbit IgG. QCM and SPR analyses demonstrated 
that FcBP-Pf_Fn self-assembles with both human IgG and rabbit IgG, and that FcBP-Pf_Fn/human 
IgG complex is stable enough not to be interfered by synthetic FcBPs (Kd = 85 nM) and components 
in rabbit serum. Fluorescently labeled FcBP-Pf_Fn and trastuzumab formed complexes that 
specifically bound to the SKBR3 human breast cancer cell line, which over-expresses target HER2, 
but not to the MCF10A non-cancerous breast cell line, which does not express HER2, as shown by 
fluorescence imaging. In addition, rabbit anti-folate receptor antibodies successfully formed non-
covalent complexes with FcBP-Pf_Fn even without any further change and these complexes 
effectively bound to the KB cell line, which over-expresses target folate receptor. 
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Figure 1. (A) Surface and ribbon diagram representations of Pf_Fn (PDB: 2JD6) from the position of 
the four-fold axis of symmetry (left) and the subunits (right). The loop region is shown in magenta, 
with the inserted FcBP and extra glycine residues shown as connected spheres. (B) Schematic 
representation of the construction of a non-covalent antibody/fluorescent labeled protein cage 
complex. (For interpretation of the references to color in this figure legend, the reader is referred to 
the web version of this article.) 
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Figure 2. (A) Size exclusion elution profiles of FcBP-Pf_Fn (top) and wt Pf_Fn (bottom). The 
samples were loaded onto a 10 × 300 mm superose 6 size exclusion column, which had been pre-
equilibrated with 50 mM phosphate, 100 mM NaCl (pH 6.5) and eluted with the same buffer at a rate 
of 0.5 ml/min. (B) Transmission electron micrographic image of 2% uracyl acetate stained FcBP-
Pf_Fn. TEM image confirmed an intact cage architecture with a uniform size distribution (C) 
Dynamic light scattering measurements of FcBP-Pf_Fn. The mean diameter of FcBP-Pf_Fn was 13.2 
nm. 
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Figure 3. QCM resonance frequency change (-ΔF) profiles of either wt Pf_Fn (solid line) and FcBP-
Pf_Fn (dashed line) on the gold QCM sensors and subsequent deposition of human IgG on the 
monolayer of FcBP-Pf_Fn. While the frequency of FcBP-Pf_Fn-monolayered QCM sensor decreased 
dramatically upon introduction of human IgG (dashed line), the frequency of wt Pf_Fn-monolayered 
QCM sensor remained unchanged (solid line) (B) SPR analyses of FcBP-Pf_Fn binding to human IgG 
immobilized gold SPR sensors. Gradual increases in SPR responses (RU) were observed upon the 
introduction of FcBP-Pf_Fn, with RU values reaching a plateau at each concentration. 
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Figure 4. Fluorescent microscopic images of SKBR3 breast cancer cells (A–C) and MCF10A breast 
cells (D–F) treated with Cy3-trastuzumab/fFcBP-Pf_Fn complexes. Trastuzumab and FcBP-Pf_Fn 
were labeled with Cy3 (Cy3-trastuzumab) and fluorescein (fFcBP-Pf_Fn), respectively. Cy3-
trastuzumab was simply mixed with fFcBP-Pf_Fn to form Cy3-trastuzumab/fFcBP-Pf_Fn complexes 
and subsequently incubated with SKBR3 breast cancer cells and MCF10A breast cells in the presence 
of excess amounts of rabbit serum. Cy3-trastuzumab and fFcBP-Pf_Fn are visualized as orange and 
green, respectively, by fluorescence microscopy. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
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Figure 5. QCM resonance frequency change (-ΔF) profiles of either wt Pf_Fn (solid line) and FcBP-
Pf_Fn (dashed line) on the gold QCM sensors and subsequent deposition of rabbit IgG on the 
monolayer of FcBP-Pf_Fn. The frequency of wt Pf_Fn-monolayered QCM sensor remained 
unchanged (solid line), whereas the frequency of FcBP-Pf_Fn-monolayered QCM sensor decreased 
dramatically upon introduction of rabbit IgG (dashed line), (B) SPR analyses of FcBP-Pf_Fn binding 
to rabbit IgG immobilized gold SPR sensors. Gradual increases in SPR responses (RU) were observed 
upon the introduction of FcBP-Pf_Fn, with RU values reaching a plateau at each concentration. 
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Figure 6. Fluorescent microscopic images of KB cells treated with fRAnti-folateR-Ab/AlexaFcBP-
Pf_Fn complexes (A–C) and AlexaFcBP-Pf_Fn only (d–E). Rabbit anti-folate receptor antibody 
(RAnti-folateR Ab) and FcBP-Pf_Fn were labeled with fluorescein (fRAnti-folateR Ab) and Alexa 
647 (AlexaFcBP-Pf_Fn), respectively. RAnti-folateR Ab was simply mixed with AlexaFcBP-Pf_Fn 
to form fRAnti-folateR-Ab/AlexaFcBP-Pf_Fn complexes and subsequently incubated with KB cells. 
fRAnti-folateR-Ab and AlexaFcBP-Pf_Fn are visualized as green and red, respectively, by 
fluorescence microscopy. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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Figure S1. Subunit protein analyses of FcBP_Pf_Fn. (A) Purified wild-type and Fc-binding peptide 
(FcBP) containing Pf_Fn were analyzed on the 13% SDS-PAGE and stained with Coomassie. Subunit 
of FcBP-Pf_Fn migrated much slower than that of wt Pf_Fn. (B) Electrospray ionization-time of flight 
(ESI-TOF) mass spectrum of the dissociated subunits of FcBP-Pf_Fn. Single Gaussian charge state 
distribution was observed indicating the presence of single protein species. 24+, 22+, and 20+ charged 
peaks of the dissociated subunits of FcBP-Pf_Fn are indicated. (C) Deconvolution of charge state 
distribution shows mass of the dissociated subunits of FcBP-Pf_Fn (calc. 22,600.7 Da; obs. 22,600.0 
Da) 
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Figure S2. QCM resonance frequency charge (-∆F) profiles of either wt Pf_Fn (black line) and FcBP-
Pf_Fn (red line) on the fold QCM sensors. Monolayer formations of wt Pf_Fn and FcBP-Pf_Fn on the 
gold QCM sensor are schematically represented on the right.  
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Figure S3. Fluorescent labeling of FcBP-Pf_Fn with fluorescein-5-maleimide (F5M) and its 
characterization. (A) FcBP-Pf_Fn was incubated with 3 molar equivalents of fluorescein-5-maleimide 
(F5M) at room temperature with vigorous shaking for 3 hrs. (B) Reaction was analyzed on the 13% 
SDS-PAGE and stained with Coomassie. F5M treated FcBP-Pf_Fn migrated slightly slower than 
untreated FcBP-Pf_Fn and no residual FcBP-Pf_Fn subunit was detected in F5M labelling reaction. 
(C) Reactions were loaded onto a 10 x 300 mm superpose 6 (Amersham Bioscience) size exclusion 
column and eluted with buffer containing 50 mM MES, 100 mM NaCl, pH 6.5 at a rate of 0.5 ml/min. 
Unreacted F5M was eluted late and indicated with *. (D) UV/Vis spectra of F5M treated (red line) 
and untreated (black line) FcBP-Pf_Fn. The strong absorbance at 488 nm, which is the absorption 
maxima of fluorescein, was only observed in the F5M treated FcBP-Pf_Fn sample.   
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Figure S4. QCM resonance frequency change (-∆F) profiles of either wt Pf-Fn (black line) labeled 
with fluorescein and FcBP-Pf_Fn (red line). Labeled with fluorescein on the gold QCM sensors and 
subsequent human IgG absorption on the monolayer of FcBP-Pf_Fn. Monolayer formations of wt 
Pf_Fn and FcBP-Pf_Fn labeled with fluorescein on the gold QCM sensor and subsequent antibody 
depositions are schematically represented on the right.  
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Figure S5. Competition experiments of FcBP-Pf_Fn binding to human IgG with synthetic FcBP. 
FcBP-Pf_Fn at a series of concentrations (5, 25, and 50 nM) in PBS, pH 7.4 was injected to human 
IgG immobilized on SPR chip at the rate of 30 μl/min. A synthetic FcBP (100nM) in the same buffer 
was injected onto FcBP-Pf_Fn-human IgG surface at a flow rate of 30μl/min for 2 min followed by 
buffer washing.  
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Chapter4. Incorporation of Thrombin Cleavage Peptide into a Protein 
Cage for Constructing a Protease-responsive Multifunctional Delivery 
Nanoplatform. 
 
4.1. Introduction 
 
Colloidal nanoparticles have been extensively studied as nanoscale multifunctional delivery vehicles 
for disease- or target-specific diagnosis and therapy.(1-6) Their nanometer-range size allows 
enhanced circulation of included materials,(7, 8) such as drugs and diagnostic probes, unlike that in 
the case of circulation of free drugs or small molecules in blood. Nanoparticles also undergo passive 
accumulation in tumor sites through the enhanced permeability and retention (EPR) effect.(9) 
Nanoparticle-based delivery systems also provide a high surface-to-volume ratio that results in a high 
cargo-loading capacity for payload delivery and a multivalent surface that can be used as a platform to 
add functional groups that improve the aqueous solubility of desired cargoes, such as drugs and 
diagnostic probes,(10, 11) as well as to attach various types of ligands for targeted delivery.(1-6) For 
early detection and localized treatment of diseases, such as cancers, and to reduce the side effects of 
therapeutics, targeted and stimulus-responsive delivery of cargoes using nanoparticle-based delivery 
systems has been extensively attempted.(12-16) Various types of chemical ligands, short peptides, and 
antibodies have been used as targeting moieties of nanoparticle-based delivery systems to enhance 
their efficiency of delivery.(1-6) For the localized release of therapeutics and target-specific diagnosis 
of symptoms, nanoparticle-based delivery systems have been designed to release encapsulated drugs 
and to exhibit diagnostic signals upon changes in pH, light, and temperature, as well as treatment with 
ligands and specific proteases.(12-17) For example, insulin-encapsulating polymeric vesicular 
polymersomes were shown to release insulin in the presence of excess glucose through the disruption 
of the block copolymer conformation.(18) Additionally, heat shock proteins that contain a peptide 
sequence cleaved by caspase remained quenched in the absence of caspase but exhibited fluorescence 
at the region where caspase was present.(19) Nanoparticle-based delivery systems are generally 
prepared from synthetic polymers,(2, 20) inorganic nanomaterials,(4, 6) and biomaterials(21-23) 
derived from various types of biological sources. Protein cages are protein-based supramolecular 
complexes that have well-defined hollow spherical architectures. Protein cages, including ferritins, 
viral capsids, and heat shock proteins, are precisely self-assembled from multiple copies of a limited 
number of subunits, which results in highly symmetric and uniformly sized architectures.(24, 25) The 
interior surfaces of protein cages have been used for encapsulation, attachment, and synthesis of 
organic and inorganic materials, whereas the exterior surfaces have been used for multivalent 
presentations of molecules, including affinity tags, antibodies, fluorophores, carbohydrates, nucleic 
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acids, and peptides, and for molecular targeting and hierarchical structure formation.(26-33) Their 
nanometer-range sizes, propensity to self-assemble into monodisperse nanoparticles of discrete shapes 
and sizes, and high degree of symmetry and polyvalence make protein cages attractive nanoplatforms 
for the development of multifunctional nanoscale delivery vehicles.(24, 25) As a model nanoscale 
delivery platform, we used ferritin, isolated from the hyperthermophilic archaeon Pyrococcus furiosus 
(Pf_Fn). Pf_Fn is expressed as a monomer and 24 identical subunits self-assemble into a spherical 
cage with inner and outer diameters of 8 and 12 nm, respectively (Figure 1).(34) Each subunit consists 
of a 4-helix bundle (helices A–D) and a tilted fifth short α-helix (helix E) connected by a flexible loop 
region which is exposed at the surface of the 4-fold symmetry axis when they assemble to form a 
spherical cage (Figure 1).(22, 34) The tilted fifth short α-helices (helix Es) are located in the interior 
space and project to the middle of the cage where they are securely isolated from the outside of the 
cage, when they assemble to form a spherical shell (Figure 1).(22, 34) Therefore, the C-terminal end 
of helix E is a good candidate site for the attachment of therapeutics and addition of cytotoxic 
materials including apoptotic peptides. To develop the Pf_Fn protein cage as a stimulus-responsive 
delivery nanoplatform in this study, we genetically modified the C-terminal end and inserted a short 
peptide (GGLVPRGSGAS) that is selectively recognized and cleaved by thrombin.(35) Thrombin is a 
trypsin-like serine proteinase that plays a critical role in the blood coagulation system to generate 
insoluble fibrin from soluble fibrinogen. It is also known that thrombin plays an important role in 
extravascular disease, cancer, cardiovascular diseases, acute kidney injury, and stroke. 
 
4.2. Material and Methods 
 
Thrombin Cleavage Peptide Insertion and Protein Cage Purification 
The sequence GGLVPRGSGAS was inserted into the 146 position of Pf_Fn by an established PCR 
protocol using primers containing extra nucleotides and pET-30b based plasmids containing genes 
encoding Pf_Fn protein with one site mutation (S98C) as a template. S98C Pf_Fn behaves almost 
identical to the wild type (wt) Pf_Fn(22, 37) and we used S98C Pf_Fn as a template protein cages 
hereafter. The amplified DNAs were used to transform the competent E. coli strain BL21 (DE), which 
resulted in the overexpression in E. coli of the Pf_Fn protein cage containing the inserted thrombin 
cleavage peptide. The resultant protein was purified as described previously.(37) We routinely 
obtained 5 mg of Thr-Pf_Fn from 1 L culture. 
 
Mass Spectrometry 
The subunit masses of untreated, chemically modified, and thrombin-treated Thr-Pf_Fn protein cages 
were analyzed using an ESI-TOF mass spectrometer (Xevo G2 TOF, Waters) interfaced to a Waters 
UPLC and an autosampler. Samples were loaded onto the MassPREP Micro desalting column 
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(Waters) and eluted with a gradient of 5–95% (v/v) acetonitrile containing 0.1% formic acid with a 
flow rate of 300 μL/min.(22) ESI generally produces a series of multiply charged ions and the charges 
are generally distributed as a continuous series with a Gaussian intensity distribution and the 
molecular masses of each species can be determined from the charges and the observed mass-to-
charge (m/z) ratio values. Mass spectra were acquired in the range of m/z 500–3000 and deconvoluted 
using MaxEnt 1 and MaxEnt 3 from MassLynx version 4.1 to obtain the average mass from multiple 
charge state distributions.(22) For clarity, only deconvoluted masses were presented. 
 
Thrombin Cleavage of Thr-Pf_Fn 
Chemically modified or intact Thr-Pf_Fn protein cages were incubated with 10 units/mL of thrombin, 
and reactions were sampled at 1, 2, 4, 6, 8, 24, and 72 h. The collected samples were analyzed by 
performing 13% acrylamide reducing SDS-PAGE, size exclusion chromatography, and mass 
spectrometry. 
 
Chemical Modifications of Thr-Pf_Fn 
Thr-Pf_Fn protein cages were incubated with 3 mol equiv of fluorescein-5-maleimide (F5M) at room 
temperature in the presence of 0.1 mM TCEP with vigorous shaking overnight. Reactions were 
dialyzed against buffer (50 mM sodium phosphate, 100 mM NaCl, pH 6.5) overnight to remove 
unreacted F5M. F5M conjugated Thr-Pf_Fn protein cages were subsequently incubated with 10 mol 
equiv of NHS-PEG4-biotin (NPB) at room temperature with vigorous shaking for 1 h, and the 
reactions were dialyzed against the same buffer (50 mM sodium phosphate, 100 mM NaCl, pH 6.5) 
overnight to remove unreacted biotins.(37) 
 
Cell Culture 
MDA MB 231 cells were obtained from the Korean cell line bank (KCLB) and cultured in RPMI1640 
medium with l-glutamine (300 mg/L), 10% FBS, and antibiotics (100 μg/mL penicillin and 50 μg/mL 
streptomycin) at 37 °C under 5% CO2. 
 
Preparation and Analysis of Fluorescence Microscopy Samples 
MDA MB 231 cells were grown on microscope cover glasses (MARIENFELD, 18 mm Ø ) in 12-well 
cell culture plates (SPL, 30012). The cells were fixed with 4% paraformaldehyde in PBS (USB, 
19943) and washed two times with PBS containing 0.1% Tween 20. The fixed cells were blocked 
with 5% BSA, 5% FBS, and 0.5% Tween 20 in PBS at 4 °C for 12 h. F5M-Thr-Pf_Fn-NPB (final 
concentration of 100 μM) in blocking buffer was applied to the blocked cells at 4 °C for 12 h and then 
10 units/mL of thrombin was added at 4 °C for 12 h. The cells were washed three times with PBS 
containing 0.1% Tween 20.(22) 
63 
4.3. Results 
 
Construction of Pf_Fn Protein Cages with Thrombin Cleavage Peptide 
To develop Pf_Fn protein cage as a stimulus-responsive delivery nanoplatform, we genetically 
inserted a short peptide (GGLVPRGSGAS) into the middle of the flexible loop connecting helices D 
and E (Thr-Pf_Fn), as described in the Experimental Section (Figure 1). Thrombin recognizes the 
amino acid sequence of LVPRGS and selectively cleaves the peptide bond between the arginine and 
glycine residues (LVPR/GS). Previously, we genetically introduced a 26 amino acid Fc-binding 
peptide into the same position and demonstrated that the loop region is tolerant to the peptide 
insertion.(22) Insertion of a thrombin cleavage peptide with extra residues (GGLVPRGSGAS) into 
the loop region was confirmed by DNA sequencing. The inserted thrombin cleavage peptides were 
exposed on the surface of the Pf_Fn protein cages and clustered around the 4-fold axis of symmetry 
(Figure 1).(22) Therefore, thrombin may not only effectively cleave the loop region but also release 
the helix E from the spherical Pf_Fn protein cages by producing holes with a diameter of 
approximately 1.5 nm at the 4-fold symmetry axis (Figure 1). To introduce additional chemical 
functionality, we substituted the glycine residue at position 173, which is the second last residue of 
the C-terminus, with cysteine (Figure 1). The interior space and surface of Pf_Fn can be utilized for 
the storage of various types of materials, such as small organic molecules, inorganic nanomaterials, 
and cytotoxic peptides.(26-33) In particular, cytotoxic peptides and small organic drug-like molecules 
can be easily incorporated into the C-terminus using genetic and chemical modifications and stored 
securely without contact with external substances.(34) Once the helix E is loaded with various types 
of cytotoxic molecules, Thr-Pf_Fn can carry these cargo molecules to the target cells and locally 
release them at the targeted sites upon thrombin treatment. Thr-Pf_Fn was overexpressed and purified 
in the same manner, as previously described.(37) Purified Thr-Pf_Fn was examined by size exclusion 
chromatography (SEC), transmission electron microscopy (TEM), dynamic light scattering (DLS), 
and mass spectrometry (MS) and compared with S98C Pf_Fn (Figure 2 and Supporting Information 
(SI), Figure 1). Thr-Pf_Fn was eluted at the same position as S98C Pf_Fn on SEC, indicating that it 
has a stable 24-mer cage architecture (Figure 2A). TEM image of negatively stained Thr-Pf_Fn 
confirmed its spherical cage-like structure with a uniform size distribution (Figure 2B), and DLS 
measurements indicated that the size of thrombin functionalized Pf_Fn (12.8 nm) was almost identical 
to that of S98C Pf_Fn (12 nm; Figure 2C). The Thr-Pf_Fn subunits had a mass of 21296.0 Da, which 
agreed with the calculated molecular mass (21294.3 Da; Figure 2D). We therefore concluded that the 
inserted thrombin cleavage peptide does not alter the integrity and stoichiometry of the Pf_Fn protein 
cage architecture. 
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Thrombin Effectively Cleaves the Loop of Thr-Pf_Fn To Release the Helix E Without 
Disrupting the Cage Architecture 
To investigate the cleavage efficiency of the inserted thrombin cleavage peptide on the loop of the 
Thr-Pf_Fn cages upon thrombin treatment, we treated intact Thr-Pf_Fn with a fixed amount of 
thrombin (10 units/mL) for desired time periods and monitored the cleavage of the inserted thrombin 
cleavage peptide using SDS-PAGE (Figure 3A). The cleavage of the inserted thrombin cleavage 
peptide on the loop of Thr-Pf_Fn cages progressed as the incubation time passed. While the amount of 
21 kDa Thr-Pf_Fn subunits decreased gradually, the new 17 kDa fragments appeared and their 
amount increased as the incubation time increased (Figure 3A). We did not observe 4 kDa fragments 
in SDS-PAGE analysis because of its small size. However, mass analyses of the cleavage reaction 
products confirmed the identity of newly generated 17 kDa fragment as a helix A–D and identified 4 
kDa fragments (Figure 3C,D) (see below for details). The cleavage reaction was almost completed 
after 1 day, and nonspecifically cleaved fragments began to appear at longer incubation times (Figure 
3A). Although SDS-PAGE and MS data demonstrated the efficient cleavage of the inserted thrombin 
cleavage peptide between helix A–D and helix E, it was not clear whether the thrombin-treated Thr-
Pf_Fn maintained its cage architecture and, if so, whether the cleaved helix E remained with the 
protein cage or was released from the protein cage. To address these questions, Thr-Pf_Fn treated 
with thrombin for a day was applied to SEC column and compared with a protein molecular weight 
standard (Figure. 3B). Two distinctly separated peaks were observed (Figure 3B). The first peak 
(indicated as *) appeared at the same position as the intact Pf_Fn cage and the second peak (indicated 
as #) appeared at the position where 3–10 kDa fragments were eluted (Figure 3B), suggesting that the 
treatment of Thr-Pf_Fn with thrombin results in not only the cleavage of the loop but also the release 
of helix E from the protein cage without disturbing the protein cage architecture (Figure 3B). To 
confirm the specific cleavage of Thr-Pf_Fn at the thrombin cleavage site (LVPR/GS) and to 
determine the identity of the components in the two separated peaks, two SEC separated fractions 
(first and second peaks) were analyzed using mass spectrometry (MS). The molecular mass of the 
components of the first and second peaks were determined to be 17752.0 and 3560.0 Da, respectively, 
which are in an excellent agreement with the corresponding predicted values of 17751.2 Da (helix A–
D) and 3561.2 Da (helix E) for cleavage at the thrombin cleavage site (LVPR/GS) (Figure 3C,D). 
TEM image of negatively stained sample and DLS measurement of sample in the first peak confirmed 
its intact cage-like structure with a uniform size distribution (SI, Figure 2). These data suggest that 
thrombin-mediated cleavage of the thrombin cleavage peptides inserted in the loop of Thr-Pf_Fn may 
generate 1.5 nm holes at the 4-fold symmetry axis in addition to the release of helix E (Figure 1). 
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Interior C-Terminal Modification of Thr-Pf_Fn for Probe Attachment and Exterior Surface 
Modification for Targeting 
The X-ray crystal structure of Pf_Fn has been solved(34) and its structural details have been 
extensively studied, which allowed us to modify the desired residues in a site-specific manner. The X-
ray crystal structure of Pf_Fn shows that helix E is situated in the interior space of the protein cage 
and its C-terminal end projects toward the middle of the interior space (Figure 1). We also genetically 
added six consecutive histidine residues to the C-terminus with a short linker and successfully 
purified them. While they exhibited almost identical morphology and stability, purified C-terminal 
histagged Pf_Fn did not bind to the nickel chelated resin, suggesting introduced histaggs are not 
exposed on the surface (SI, Figure 3). Therefore, the C-terminal end of helix E is a suitable location to 
attach various types of organic molecules chemically or to add extra residues genetically because it is 
situated in the interior space of the protein cage being perfectly isolated from the outside. Lysine 
residues on the surface of protein cages have been used for the attachment of various types of 
ligands.(24, 25, 31, 32) The surface of Thr-Pf_Fn has eight lysines per subunit and they would be 
easily labeled with various types of N-hydroxysuccinimide-ester (NHS-ester) functionalized 
molecules. To adapt Thr-Pf_Fn protein cages as protease-responsive targeted delivery nanoplatforms, 
we attached a cysteine-reactive fluorescent probe (fluorescein-5-maleimide, F5M) as a model cargo at 
the end of helix E (G173C), and we conjugated amine reactive targeting moieties (NHS-PEG4-biotin, 
NPB) on the surface of Thr-Pf_Fn. Each subunit of Thr-Pf_Fn has only one cysteine at position 173 
and is located in the interior space, where it is protected from outside but accessible to small 
molecules. Thr-Pf_Fn was treated with F5M overnight and applied to SEC column to evaluate the 
coelution of F5M and Thr-Pf_Fn protein cages and to remove unreacted F5M (SI, Figure 4). F5M-
conjugated Thr-Pf_Fn was eluted at the same position as untreated Thr-Pf_Fn with a high absorption 
at 488 nm, which is the maximum absorption wavelength of fluorescein, suggesting that F5M was 
effectively labeled and that its labeling did not alter the cage architecture (SI, Figure 4A,B). Mass 
measurements and SDS-PAGE finding for the SEC fractions confirmed that all the Thr-Pf_Fn 
subunits were labeled with F5M (SI, Figure 3C,D). Additional surface modification was subsequently 
achieved using NPB and 1–4 biotins were attached to each Thr-Pf_Fn subunit and two biotins per 
subunit (48 biotins per protein cage) were attached on average (SI, Figure 4E). 
 
Monitoring the Release of Fluorescent-Probe-Labeled Helix E upon Thrombin Treatment 
To test whether fluorescently labeled helix E can be as effectively released from Thr-Pf_Fn protein 
cages upon thrombin treatment as unlabeled helix E, the F5M-labeled Thr-Pf_Fn (F5M-Thr-Pf_Fn) 
protein cage was treated with thrombin under the same conditions as unlabeled Thr-Pf_Fn, and the 
reaction products were analyzed using the same methods. The Thr-Pf_Fn protein cages without helix 
E and the F5M-labeled helix E was separated on the SEC and their identities were confirmed by 
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UV/vis spectrophotometry and mass spectrometry (Figure 4). Although the Thr-Pf_Fn protein cages 
with helix E removed were eluted (Figure 4A, top, *) at the same position as the untreated F5M-Thr-
Pf_Fn protein cages (Figure 4A, bottom), the absorption values at 488 nm decreased significantly, 
unlike that observed in the case of the untreated F5M-labeled Thr-Pf_Fn protein cages (Figure 4A,B). 
However, the second peak (Figure 4A, top, #) exhibited high absorption at 488 nm and was eluted at 
the same position as that of the cleaved helix E in Figure 3, suggesting F5M-labeled helix E was also 
effectively cleaved and released upon thrombin treatment, even after F5M conjugation (Figure 4A,B). 
The first and second peaks represent masses of 17752.0 and 3987.0 Da, respectively, which are well 
matched with the calculated subunit mass for Thr-Pf_Fn with helix E removed (helix A–D, 17751.2 
Da) and the calculated mass of F5M-labeled helix E (3988.5 Da; Figure 4C,D). However, a slight 
absorption at 488 nm was observed in the first fraction. It may result from the cleaved residual F5M-
labeled helix E remained inside of the cleaved Pf_Fn protein cages rather than uncleaved F5M-Thr-
Pf_Fn because we could not detect uncleaved F5M-Thr-Pf_Fn subunit with mass spectrometric and 
SDS-PAGE analyses. However, we can not completely rule out the possibility of the limit of detection 
of those analytical methods. 
 
Targeted Delivery of F5M-Thr-Pf_Fn-NPB and the Controlled Release of Fluorescent-Probe-
Labeled Helix E Triggered by Thrombin Treatment 
Biotin is a member of the vitamin family (vitamin B12) and is known to be more abundant in cancer 
cells than in normal cells.(20, 38) Excess amounts of biotin are known to facilitate the proliferation of 
cancer cells.(20, 38) Cancer cells generally overexpress biotin-specific receptors on their surface to 
uptake more biotin. Because the interaction between biotin and the biotin receptor is specific and 
strong, biotin-specific receptors are good candidates for targeting sites for the active delivery of 
cargo.(20, 38) To impart a targeting capability to the F5M-labeled Thr-Pf_Fn (F5M-Thr-Pf_Fn) 
protein cage, we additionally modified the surface of F5M-Thr-Pf_Fn with NPB (F5M-Thr-Pf_Fn-
NPB) and two biotins per subunit (48 biotins per protein cage) were attached on average (Supporting 
Information, Figure 4E). We obtained dual functionalized Thr-Pf_Fn protein cages that 
simultaneously contained a fluorescent probe (F5M) inside the cage and a targeting ligand (NBP) on 
the surface of the cage. To demonstrate specific binding of the dual functionalized Thr-Pf_Fn (F5M-
Thr-Pf_Fn-NPB) to the target cells and the thrombin-responsive release of helix E, we chose MDA 
MB 231 cells as the target cell line. MDA MB 231 cells are known to overexpress biotin-specific 
receptors on their surface and selectively catch external biotins.(20) F5M-Thr-Pf_Fn-NPB was 
incubated with MDA MB 231 cells and visualized by fluorescence microscopy (Figure. 5). F5M-Thr-
Pf_Fn, which does not have targeting ligands on its surface, was also treated to MDA MB 231 cells in 
parallel as the control. While F5M-Thr-Pf_Fn did not bind to MDA MB 231 cells at all (Figure 5A), 
F5M-Thr-Pf_Fn-NPB specifically bound to MDA MB 231 cells (Figure 5B). The binding of F5M-
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Thr-Pf_Fn-NPB to MDA MB 231 cells was inhibited by free biotins in a dose-dependent manner (SI, 
Figure 5), suggesting that F5M-Thr-Pf_Fn-NPB binding to the cells is mediated by specific biotin–
biotin receptor interactions. However, MDA MB 231 cells treated with F5M-Thr-Pf_Fn-NPB 
completely lost their fluorescent signals upon thrombin treatment and subsequent washing (Figure 
5C). These data suggest that F5M-labeled helix E was effectively cleaved by thrombin and removed 
from the bound Thr-Pf_Fn even when F5M-Thr-Pf_Fn-NPB was bound tightly to the target cells. 
Together, these results indicate that the Thr-Pf_Fn protein cage can serve as a stimuli-responsive 
delivery nanoplatform through combinations of genetic and chemical modifications followed by 
protease treatment. Because Thr-Pf_Fn has multiple sites and spaces available to address various 
types of functionalities, it may constitute a versatile nanoplatform that can be adapted for a variety of 
functions. The interior cavity and surface of Thr-Pf_Fn can be utilized for covalent attachment and 
encapsulation of small organic molecules, such as drugs and therapeutic reagents, encapsulation of 
preformed therapeutic, and diagnostic nanoparticles, or insertion of functional peptides, such as 
apoptotic and cytotoxic peptides. Peptide-based therapeutics is thought to be superior to antibody 
therapeutics because it is easy to be synthesize and genetically manipulate, and it requires low cost to 
produce.(39, 40) In addition to the interior space, Thr-Pf_Fn provides an exterior surface for 
displaying various types of targeting ligands, including synthetic ligands and targeting peptides that 
are screened by phage and cell surface display techniques.(39, 41, 42) Mixing-and-matching 
approaches for simultaneous interior and exterior modifications will expand the possibility of utilizing 
protein cages as multifunctional nanoscale delivery platforms and provide new opportunities for 
developing new theranostic nanoplatforms. 
 
4.4. Conclusion and Discussion 
 
We have developed a multifunctional protein cage-based delivery nanoplatform that can hold cargo 
molecules inside securely, deliver them to the targeted sites, and release them to the targeted cells 
upon triggering by a protease. Thr-Pf_Fn was prepared by genetically inserting the thrombin cleavage 
peptide into the flexible loop region of Pf_Fn and substituting C-terminal glycine with cysteine 
(G173C). The inserted thrombin cleavage peptides were clustered at a 4-fold axis of symmetry 
exposed on the surface of the protein cage and the introduced cysteine residue was situated in the 
interior cavity. Thrombin recognized and selectively cleaved the inserted peptide resulting in the 
release of the C-terminal helix E including cysteine 173 residue as well as the production of 1.5 nm 
holes at the 4-fold symmetry axes. The introduced cysteine (G173C) was labeled with fluorescent 
probes (fluorescein) for cell imaging and the lysine residues on the surface of Thr-Pf_Fn were 
subsequently labeled with targeting ligands (biotin). Fluorescence microscopic analyses demonstrated 
that dual functionalized F5M-Thr-Pf_Fn-NPB specifically bound to the MDA MB 231 cell line, 
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which overexpresses biotin specific receptors on its surface, and subsequent thrombin treatment 
completely eliminated the fluorescence signal because of selective removal of fluorescent-probe-
labeled C-terminal helix E. 
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Figure 1. Schematic representation of thrombin cleavage peptide insertion, cleavage of the inserted 
peptides, protease-responsive C-terminal helix E release, and 1.5 nm hole generation. Surface and 
ribbon diagram representations of Pf_Fn (PDB: 2JD6) from the position of the 4-fold axis of 
symmetry (A) and the subunits (B). The loop region and helix E are shown in magenta, with the 
inserted thrombin cleavage peptide. The inserted residues and conjugated fluorophores are shown as 
connected yellow and green spheres, respectively. 
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Figure 2. (A) Size exclusion elution profiles of Thr-Pf_Fn (top) and S98C Pf_Fn (bottom). The 
samples were loaded onto a 10 × 300 mm superose 6 size exclusion column, which had been pre-
equilibrated with 50 mM phosphate and 100 mM NaCl (pH 6.5) and then eluted with the same buffer 
at a rate of 0.5 mL/min. (B) Transmission electron micrographic (TEM) image of 2% uracyl acetate 
stained Thr-Pf_Fn. The TEM image confirmed an intact cage architecture with a uniform size 
distribution. (C) Dynamic light scattering measurements of Thr-Pf_Fn. The mean diameter of Thr-
Pf_Fn was 12.8 nm. (D) Molecular mass measurement of the dissociated subunits of Thr-Pf_Fn (calcd, 
21294.3 Da; obs, 21296.0 Da). 
 
 
 
 
 
 
71 
 
 
 
 
 
Figure 3. (A) SDS-PAGE analyses of thrombin treated Thr-Pf_Fn. Reactions were sampled at 1, 2, 4, 
6, 8, 24, and 72 h, as indicated. (B) Size exclusion elution profiles of thrombin treated Thr-Pf_Fn (top) 
and SEC molecular weight standard (bottom). The SEC molecular weight standard contained bovine 
thyroglobulin (670 kDa), bovine γ-globulin (158 kDa), horse myoglobin (17 kDa), and vitamin B12 
(1.35 kDa). (C) Molecular mass measurement of the first SEC fraction (*) of thrombin-treated Thr-
Pf_Fn identified the C-terminal helix E-removed Thr-Pf_Fn subunit (calcd, 17751.2 Da; obs, 17752.0 
Da). (D) Molecular mass measurement of the second SEC fraction (#) of thrombin-treated Thr-Pf_Fn 
identified the released C-terminal helix E (calcd, 3561.2 Da; obs, 3560.0 Da). 
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Figure 4. (A) Size exclusion elution profiles (280 nm [solid lines] and 488 nm [dashed lines]) of 
thrombin-treated F5M-Thr-Pf_Fn (top) and untreated F5M-Thr-Pf_Fn (bottom). The samples were 
loaded onto a 10 × 300 mm superose 6 size exclusion column, which had been pre-equilibrated with 
50 mM phosphate, 100 mM NaCl (pH 6.5), and eluted with the same buffer at a rate of 0.5 mL/min. 
(B) UV/vis spectra of untreated F5M-Thr-Pf_Fn (black line) and thrombin-treated first (blue line) and 
second (red line) SEC fractions of F5M-Thr-Pf_Fn. (C) Molecular mass measurement of the first SEC 
fraction of thrombin-treated F5M-Thr-Pf_Fn identified the F5M-conjugated C-terminal helix E-
removed Thr-Pf_Fn subunit (calcd, 17751.2 Da; obs, 17752.0 Da). (D) Molecular mass measurement 
of the second SEC fraction of thrombin-treated F5M-Thr-Pf_Fn identified the F5M-conjugated C-
terminal helix E (calcd, 3988.5 Da; obs, 3987.0 Da). 
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Figure 5. Fluorescent microscopic images of MDA MB 231 cells incubated with F5M-Thr-Pf_Fn (A, 
D) or F5M-Thr-Pf_Fn-NPB (B, E). F5M-Thr-Pf_Fn-NPB treated MDA MB cells were subsequently 
incubated with thrombin, washed, and fluorescently imaged (C, F). Thr-Pf_Fn protein cages and 
nuclei were visualized as green and blue, respectively, by fluorescence microscopy. 
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Figure S1. Molecular mass measurements of S98C Pf_Fn (A, calc. 20325.2; obs, 20327.0) and 
Thr_Pf_Fn (C, calc. 21294.3; obs. 21296.0).  (B) Transmission electron micrographic (TEM) image 
of 2% uracyl acetate stained S98C Pf_Fn. The TEM image confirmed an intact cage architecture with 
a uiform size distribution. (D) SDS-PAGE analyses of wt_Pf_Fn (left line) and Thr_Pf_Fn (light line).  
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Figure S2. Dynamic light scattering measurement of thrombin treated Thr_Pf_Fn. The mean diameter 
of thrombin treated Thr-Pf_Fn was 13.2 nm. (B) Transmission electron micrographic (TEM) image of 
2% uracil acetate stained thrombin treated Thr_Pf_Fn.  
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Figure S3. (A) Schematic representation of construction of C-terminal histagged Pf_Fn (Thr-
Pf_Fn_C-histag) (B) Transmission electron micrographic (TEM) image of 2% uracil acetate stained 
thrombin treated Thr-Pf_Fn_C-histag. (C) Size exclusion chromatographic profile. (D) Dynamic light 
scattering measurement of Thr-Pf_Fn_C-histag. The mean diameter of Thr-Pf_Fn_C-histag was 13.5 
nm. (E) Histrap (Ni-chelated resin column) elution profile of Thr-Pf_Fn_C-histag and SDS-PAGE of 
fractions. All Thr-Pf_Fn_C-histag protein cages flowed through histrap column without binding.  
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Figure S4. Size exclusion elution profiles (280 nm [solid lines] and 488 nm [dashed lines]) of F5M-
Thr-Pf_Fn (top) and Thr-Pf_Fn (bottom). Later two large peaks come from unreacted F5M (B) 
UV/Vis spectra of F5M- Thr-Pf_Fn (solid lines) and Thr-Pf_Fn (dashed lines). (C) Molecular mass 
measurement of F5M- Thr-Pf_Fn (second line), and thrombin treated F5M- Thr-Pf_Fn (third line). (E) 
Molecular mass measurement showed a mass of biotin conjugated F5M- Thr-Pf_Fn (F5M- Thr-
Pf_Fn-NPB). One to four biotin conjugated F5M- Thr-Pf_Fn were observed as indicated.  
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Figure S5. Dose-dependent inhibition of F5M_ Thr-Pf_Fn-NPB binding to MDA MB 231 cells by 
co-incubating with free biotins. MDA MB 231 cells were co-incubated with F5M- Thr-Pf_Fn-NPB 
with free biotins (0 μM (C), 0.5 μM (D), 5 μM (E) or 20 μM (F), respectively) at 4 ℃ for 12 hours 
and the cells were washed 3 times with PBS containing 0.1% Tween 20. Fluorescent microscopic 
images of free biotin treated cells clearly showed significant decrease of fluorescent intensity.   
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Chapter 5.  Ferritin Protein Cage Nanoparticles as Versatile Antigen 
Delivery Nanoplatforms for Dendritic (DC)-based Vaccine Development 
 
5.1. Introduction 
 
Boost your own defence systems; ferritin protein cage nanoparticles (FPCNs) were developed as 
versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development. 
Antigenic peptides were effectively delivered to DCs by FPCNs and differentiated CD8
+
 and CD4
+
 T 
cells into effective cytotoxic T cells and functional CD4
+
 Th1 and Th2 cells producing IFN-γ/IL-2 and 
IL-10/IL-13 cytokines, respectively. A primary goal of vaccination is to generate robust and specific 
immune responses against infectious pathogens or internally generated abnormal cells, and to 
efficiently mount faster and stronger immune response upon their actual invasion or occurrence. An 
effective vaccine must induce antigen-specific cellular and humoral immune responses without severe 
side-effects.
1
 Dendritic cells (DCs) are the most potent professional antigen-presenting cells that 
initiate and control antigen-specific immune responses. DCs efficiently internalize, process, and 
present antigens to naïve T cells and induce their proliferation and differentiation into effector cells; 
CD8
+
 cytotoxic T cells to kill infected target cells or CD4
+
 helper T cells to secrete cytokines and 
facilitate diverse forms of cellular and humoral immunity.
2
 Therefore, based on these unique features 
of DCs in the immune system, DC-based vaccine development has been a promising approach to 
direct antigen-specific adaptive immunity in vivo.
3, 4 and 5
 Many of the approaches for vaccination have 
focused on utilizing inactivated or live attenuated disease-causing pathogens.
6
 In particular, virus-like 
particles (VLPs) derived from human viruses, including Hepatitis B and human papilloma VLPs, have 
been extensively used as human viral vaccines and significantly contributed to prevent viral 
diseases.
7 and 8
 However, there are limitations for developing vaccines for non-pathogen derived 
diseases, such as cancer, in these approaches and systematic studies of antigenic epitope-specific 
immune responses are needed. It is necessary to develop simple and controllable antigen delivery 
systems which can carry a variety of protein antigens or antigenic peptides. Recently, nano-sized 
materials, including polymers, inorganic nanoparticles, liposomes, and/or VLP, have been extensively 
used as antigen delivery nanoplatforms for studying antigen-specific immune responses and further 
applied them to follow-up vaccine development.
9, 10, 11, 12, 13, 14, 15, 16 and 17
 However, there is a limited 
amount of study utilizing protein cage nanoparticles to deliver antigens to DCs for immunization and 
vaccination. FPCNs are attractive delivery nanoplatforms for in vivo application, because they are 
composed of biodegradable biopolymers, or proteins, having a well-defined hollow spherical 
architecture with inner and outer diameters of 8 and 12 nm, respectively, and precisely self-assemble 
from 24 copies of identical 20 kDa subunits which can be easily and accurately manipulated by 
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genetic modifications and chemical bioconjugations.
16, 18 and 19
 FPCN has multiple regions which are 
tolerant of the peptide insertion potentially offering the sites for genetic insertion of various types of 
antigenic peptides and small protein antigens.
20 and 21
 Ferritin, isolated from hyperthermophile 
Pyrococcus furiosus, has been successfully used as a template for biomimetic nanomaterials syntheses 
22, 23 and 24
 and multifunctional delivery nanoplatforms. 
20 and 21
 Ovalbumin (OVA) has been studied as a 
model antigen for a long time since immunogenic epitopes as well as transgenic mouse models had 
been well-established. Genetically engineered OT-1 or OT-2 mice have CD8
+
 OT-1 T cells or CD4
+
 
OT-2 T cells, of which T cell receptors are specific for OT-1 peptides (SIINFEKL) or OT-2 peptides 
(ISQAVHAAHAEINEAGR), respectively.
25 and 26
 OT-1 and OT-2 peptides are CD8
+
 and CD4
+
 T cell 
epitopes corresponding to OVA257-264 and OVA323-339, respectively.
27 and 28
 Thus, the presentation of 
OT-1 peptides by DCs to OT-1 T cells leads to proliferation and differentiation of cytotoxic CD8
+
 T 
cells, while the presentation of OT-2 peptides to OT-2 T cells results in proliferation and subsequent 
differentiation of cytokine producing CD4
+
 T cells. 
 
5.2. Material and Methods 
 
Incorporation of antigen peptides, OT-1 and OT-2, and OTs-FPCNs purification 
OT-1 peptide (SIINFEKL) or OT-2 peptide (ISQAVHAAHAEINEAGR) was inserted into the 146 
position or added to the C-terminus of wild-type (WT) FPCN by an established PCR protocol using 
primers containing extra nucleotides and pET-30b based plasmids containing genes encoding FPCN 
as a template. The amplified DNAs were used to transform the competent Escherichia coli strain 
BL21 (DE), which resulted in the over-expression in E. coli of FPCN containing OT-1 or OT-2 
peptides. The resultant proteins were purified as described previously. 
24
 The endotoxin levels of the 
resulting samples were quantified after endotoxin removal by Triton X-114 (Sigma; St. Louis, MO) 
and the endotoxin levels of the resulting samples were quantified using a Limulus Amebocyte Lysate 
assay (Genescript, Piscataway, NJ). The resulting levels were all less than 0.15 EU/ml. The protein 
concentrations were determined by Bradford assay (Bio-Rad, Hercules, CA). Protein concentrations 
used in this study were determined in a way so that approximately similar amounts of peptides were 
contained either in FPCNs or in soluble OVA protein. 50 μg of OT-1-FPCN contains approximately 
similar amounts of OT-1 peptides as that of 100 μg of soluble OVA protein, since each protein 
molecular has one OT-1 peptide and the molecular weight of OVA protein (45 kDa) is twice larger 
than that of OT-1-FPCN subunit (22 kDa). Similar approaches were applied to OT-2 peptides. The 
concentrations of model antigen OVA used in this study were determined based on numerous 
literatures. In general, 1-5 mg/ml of OVA and 50-500 μg of OVA per mouse have been used in in 
vitro assay and in vivo assay, respectively, even though there might be variations depending on its 
own experimental purposes and conditions. In particular, our rationale in this study for the 
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concentration of the model antigen OVA was based on the previous study by the late Ralph M. 
Steinman’s group.29 
 
Mass spectrometry 
The subunit masses of WT-FPCN and FPCN derivatives were analyzed using an ESI-TOF mass 
spectrometer (Xevo G2 TOF, Waters) interfaced to a Waters UPLC and an autosampler. Samples 
were loaded onto the MassPREP
TM
 Micro desalting column (Waters) and eluted with a gradient of 5-
95% (v/v) acetonitrile containing 0.1% formic acid with a flow rate of 300 μl/min.30 ESI generally 
produces a series of multiply charged ions and the charges are generally distributed as a continuous 
series with a Gaussian intensity distribution and the molecular masses of each species can be 
determined from the charges and the observed mass-to-charge (m/z) ratio values. Mass spectra were 
acquired in the range of m/z 500-3,000 and deconvoluted using MaxEnt 1 and MaxEnt 3 from 
MassLynx version 4.1 to obtain the average mass from multiple charge state distributions. 
30
 For 
clarity, only deconvoluted masses were presented. 
 
Mice 
C57BL/6 mice were purchased from Taconic, and OT-1 and OT-2 (both C57BL/6 background) mice 
were purchased from the Jackson Laboratory. All mice were maintained under specific pathogen-free 
conditions and used at 6-8 weeks with Institutional Animal Care and Use guidelines. The Institutional 
Animal Care and Use Committee of the Ulsan National Institute of Science and Technology (UNIST) 
approved the in vivo animal experiments conducted in this study. 
 
Isolation of splenic DCs and OVA-specific T cells 
Single cell suspensions of splenocytes were prepared with 400 U/ml collagenase D (Roche) and 
CD11c
+
 cells were positively enriched with MACS sorting (Miltenyl Biotech). OVA-specific CD8
+
 or 
CD4
+
 T cells were prepared from OT-1 or OT-2 mice, respectively. Briefly, single cell suspensions 
from lymph nodes and spleens were prepared and CD8
+
 T cells or CD4
+
 T cells were positively 
enriched by MACS sorting. Sorted T cells showed > 98% purity as detected by flow cytometry. All 
flow cytometry data were acquired by BD FACS Calibur and analyzed by FlowJo software (TreeStar). 
 
Protein phagocytosis 
Phagocytosis of FPCNs by DCs was determined by pHrodo dye (Invitrogen). Briefly, each FPCN was 
labeled with pH-sensitive pHrodo dye and the remaining free dye was removed by extensive dialysis 
with multiple change of dialysis buffer. The proteins were then incubated with DCs for 2 hours either 
at 4 °C or 37 °C. The DCs were washed thoroughly and the fluorescent intensity of pHrodo by 
phagocytosis was measured by flow cytometry. 
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CFSE-dilution assay to detect antigen specific T cell proliferation in vitro and in vivo 
For in vitro OVA-specific T cell proliferation assay, OT-1 or OT-2 T cells were stained with 0.5 μM 
of CFSE (Invitrogen) at 1 × 10
7
 cells/ml for 10 min at 37 °C. DCs were pulsed with indicated proteins 
for 3 hours, washed and then co-cultured with the CFSE-labeled T cells at a ratio of 1:3 (DC, 1 × 10
5
: 
T cell, 3 × 10
5
) in a 96-well U-bottom plate at 37 °C. After 4 days, cells were harvested and then 
stained for Vβ5.1/5.2 (Biolegend), Vα2 and CD8 or CD4 (all from BD). For in vivo OVA-specific T 
cell proliferation assay, naïve C57BL/6 mice were adoptively transferred with 5 μM CFSE-labeled 
OT-1 or OT-2 T cells intravenously at day − 1. At day 0, mice were injected with indicated proteins in 
the footpads subcutaneously (s.c.) in the presence of 50 μg of polyinosinic-polycytidylic acid (poly 
(I:C)) (InvivoGen) as an adjuvant. At day 3, single cell suspensions were prepared from lymph nodes. 
OVA-specific T cells (Vβ5.1/5.2+Vα2+CD8+ or Vβ5.1/5.2+Vα2+CD4+) were gated and progressive 
halving of CFSE fluorescence per cell was measured by flow cytometry. 
 
In vivo cytotoxic T lymphocyte (CTL) assay 
For in vivo CTL assay, mice were immunized subcutaneously (s.c.) with PBS or indicated proteins in 
the presence of 50 μg of poly (I:C) as an adjuvant. At day 14, mice were intravenously injected with 
1:1 mixtures, 7 × 10
6
 of each, of OT-1 peptide-pulsed (5 μM CFSE-labeled, CFSEhi) and unpulsed 
(0.5 μM CFSE-labeled, CFSElow) syngeneic splenocytes. Fourteen to sixteen hours later, single cell 
suspensions were prepared from lymph nodes and the OVA-specific CTL activity was evaluated by 
flow cytometry. 
 
Cytokine assay 
For OVA-specific CD4
+
 T cell cytokine production assay, DCs were pulsed with indicated proteins 
for 3 hours. The DCs were thoroughly washed and then co-cultured with OT-2 T cells at a ratio of 1:3 
(DC, 1 × 10
5
: T cell, 3 × 10
5
) in a 96-well U-bottom plate at 37 °C. After 48-72 hours, supernatants 
were collected and IFN-γ, IL-2, IL-10 and IL-13 production was analyzed by CBA flex sets (BD 
Bioscience) and flow cytometry. Data were analyzed with FCAP Array software. *P < 0.05, 
**P < 0.01, ***P < 0.001. 
 
Statistics 
Results are expressed as mean ± s.d. We used EXCEL or PRISM 4.0 program (GraphPad Prism) and 
performed nonparametric Mann-Whitney U test. The P values < 0.05 were considered significant. 
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5.3. Results 
 
Construction of OT peptide-containing ferritin protein cage nanoparticles (OT-FPCNs) 
We utilized ferritin protein cage nanoparticles (FPCN) as antigen delivery nanoplatforms for DC-
based vaccine development and investigated DC-mediated antigen-specific immune responses 
(Figure 1). In order to evaluate the efficacy of FPCNs as antigen delivery nanoplatforms to DCs, we 
genetically introduced OT-1 and OT-2 peptides (together, OT peptides) either into the interior cavity 
(FPCN-C) or onto the exterior surface of FPCN (FPCN-L) (Figure 2, A and Supplementary Figure 1, 
A). Previously, we genetically introduced 22 consecutive amino acids to the C-termini of FPCN 
subunits and 26 amino acid Fc-binding peptide into the middle of the flexible loop of FPCN. 
20 and 21
 
We demonstrated that these regions are tolerant of the peptide insertions and are located in the interior 
cavity and on the surface of FPCN, respectively. 
20 and 21
 Insertions were confirmed by DNA 
sequencing and molecular mass measurements of the dissociated subunits of OT peptide inserted 
FPCN-C (OT-1-FPCN-C or OT-2-FPCN-C) (Figure 2, B). OT-1-FPCN-C and OT-2-FPCN-C 
(together, OT-FPCN-C, and likewise for OT-FPCN-L, see Supplementary Figure 1) were eluted at the 
same position on size exclusion chromatography as wild-type FPCN (WT-FPCN), which do not have 
any OT peptide insertions (Figure 2, C). Transmission electron micrographic images of negatively 
stained OT-FPCN-C exhibited hollow spherical architecture with a uniform size distribution (~ 13 nm) 
(Figure 2, D). OT-FPCN-L also exhibited almost identical cage architecture to WT-FPCN and OT-
FPCN-C ( Supplementary Figure 1). Zeta potential measurements revealed that OT-peptide inserted 
FPCNs had slightly lower negative surface charges (− 21 to − 28 mV) than that of wt FPCN 
(− 19.4 mV) (Supplementary Figure 2) probably due to the introduced peptides, whereas dynamic 
light scattering (DLS) measurements of wt and OT-peptide inserted FPCNs confirmed the uniformed 
hydrodynamic diameters of 13.2 ± 0.4 nm regardless of peptide insertion (Supplementary Figure 3). 
These results indicate that the insertions of a series of OT peptides do not significantly alter the 
integrity and stoichiometry of FPCN cage architecture and provide rationale for incorporation of other 
antigenic peptides. 
 
All FPCNs carrying OT peptides were efficiently phagocytosed by DCs 
To induce antigen-specific T cell responses, protein antigens must be first internalized by DCs, 
processed within endosomes, and presented on the surface as a complex of peptide: MHC 
molecules.
31
 In order to examine uptake of WT-FPCN and FPCN derivatives by DCs, each FPCN 
derivative and OVA protein were labeled with pHrodo dye, which is an indicator of phagocytosis as it 
greatly increases in fluorescence at low pH.
32
 Proteins were then incubated with DCs, and the 
fluorescence changes due to phagocytosis were measured by flow cytometry. Fluorescence intensity 
of pHrodo labeled FPCNs increased dramatically at 37 °C suggesting that all FPCNs, regardless of 
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insertions of OT peptides or configurations, were phagocytosed as efficiently as the control soluble 
OVA protein (Figure 3).  
 
Delivered OT-1 and OT-2 peptides were successfully induced proliferations of OT-1-specific 
CD8
+
 cells and OT-2-specific CD4
+
 T cells, respectively, both in vitro and in vivo 
To determine whether the phagocytosed OT peptides carried by FPCNs would be processed and 
presented to MHC-restricted OT peptide specific CD8
+
 or CD4
+
 T cells leading to their antigen-
specific T cell proliferation in vitro, DCs were pulsed with either OT-1-FPCNs (OT-1-FPCN-C or 
OT-1-FPCN-L) or OT-2-FPCNs (OT-2-FPCN-C or OT-2-FPCN-L) for three hours and were washed 
to ensure the presentation of only processed antigens. DCs were then co-cultured with 
carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-1 or OT-2 T cells, respectively, for four 
days and the proliferation of OT-1 peptide specific CD8
+
 T cells or OT-2 peptide specific CD4
+
 T 
cells was measured by flow cytometry. All concentrations of the FPCNs shown are of the total 
construct. If CFSE-labeled OT-1 or OT-2 T cells are effectively stimulated by delivered and presented 
antigens by DCs via FPCNs, clonal expansions of antigen specific T cells would occur, resulting in 
serial dilutions of CFSE.
33
 While CFSE signals of OT T cells co-cultured with DCs pulsed with PBS 
or WT-FPCN remained unchanged, those of OT T cells co-cultured with DCs pulsed with OVA 
protein (a positive control) or OT-FPCNs appeared as a series of peaks with lower CFSE fluorescence 
intensities indicating that OT antigenic peptides delivered to DCs by FPCNs effectively induce 
antigen-specific CD8
+
 or CD4
+
 T cell proliferations in vitro (Figure 4). We further investigated 
dosage-dependent OT peptide-specific CD8
+
 or CD4
+
 T cell proliferation. As OT-FPCN 
concentrations decreased, the proliferation also decreased, confirming the specificity of proliferative 
response (Supplementary Figure 4). We did not observe any significant difference in T cell 
proliferations between OTs-FPCN-C and OTs-FPCN-L configurations in this particular in vitro 
setting (Supplementary Figure 4). In addition, we deleted one amino acid of the OT-2 peptide 
(ISQAVHAAHAEINEAGR, underlined amino acid is missing, OT-2′-FPCNs) (Supplementary 
Figure 5) and observed that FPCNs carrying such modified OT-2 peptides could not induce T cell 
proliferation in vitro, further confirming the specificity of T cell proliferation (Supplementary 
Figure 6). Antigen-specific T cell proliferation induced by FPCN antigen delivery was also confirmed 
in vivo. Naïve mice were adoptively transferred intravenously with CFSE-labeled OT-1 or OT-2 T 
cells and were immunized with OT-1-FPCNs or OT-2-FPCNs, respectively, or with WT-FPCN in the 
presence of poly (I:C) as an adjuvant. OVA protein (100-500 μg per mouse) was also used as a 
positive control in parallel. Since OVA protein induced similar level of proliferation of OVA-specific 
T cells when compared to equivalent amount of free synthetic OT peptides (data not shown), we used 
OVA protein as a positive control hereafter to directly compare the process and the efficacy of OT 
peptides in OVA protein and those in FPCNs. Similar to OT peptide specific T cell proliferation data 
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in vitro, CFSE signals of OT T cells from mice immunized either with OVA protein (a positive 
control) or OT-FPCNs showed serially diluted peaks with decreasing CFSE fluorescence intensity, 
suggesting that OT antigenic peptides delivered to DCs by FPCNs effectively induce antigen-specific 
CD8
+
 or CD4
+
 T cell proliferations in vivo (Figure 5). We did not observe configuration-dependent 
variations in antigen-specific T cell proliferation at 250 μg of OT-2-FPCNs per mouse, of which the 
amount of OT-2 peptide epitope contained in the OT-2-FPCNs was similar to that of 500 μg of 
soluble OVA protein per mouse. However, at much lower dosages, we found a significant difference 
in antigen-specific CD4
+
 T cell proliferation in vivo depending on FPCN configurations; much less 
proliferative responses were observed in the group where antigens were delivered via OT-FPCN-L in 
comparison to OT-FPCN-C (Supplementary Figure 7). Although the loop region, the region of OT 
peptide insert, is located on the surface of FPCN, it is located in the middle of the protein sequence. 
Thus, the loop structure of epitopes carried by OT-FPCN-L might not be processed as efficiently as 
the epitopes at the C-terminal by DCs in vivo, leading to the decreased antigen-specific T cell 
proliferation. In the case of OT peptide-specific CD8
+
 T cell proliferative responses, the differences 
due to FPCN configuration were only observed at the lowest dosage tested, 0.5 μg injected 
subcutaneously per mouse (Supplementary Figure 7, left panel). Generally, OT-1 T cells are known to 
be more proliferative in response to OVA protein than OT-2 T cells.
34
 Hence the threshold for 
extensive proliferation of CD8
+
 T cells seems to be lower, and above this threshold, saturated 
proliferative activity overwhelms the effect of distinct FPCN configurations. Taken together, these 
data clearly demonstrated the successful uptake, process, and presentation of antigens delivered to 
DCs by FPCNs both in vitro and in vivo.  
 
Naïve mice immunized with FPCN carrying OT-1 peptides efficiently differentiate OT-1 CD8
+
 T 
cells into functional effector cytotoxic T cells and selectively killed antigen-specific target cells 
We next investigated whether the activated T cells could be differentiated into functional effector T 
cells, which is essential in effective adaptive immune responses. The effector functions of antigen-
specific T cells were determined by cytotoxic T lymphocyte (CTL) assay for CD8
+
 T cells and 
cytokine production for CD4
+
 T cells. We utilized in vivo CTL assay where OT-1-FPCN 
immunization would generate OT-1 peptide specific CD8
+
 cytotoxic T cells in vivo and would only 
kill OT-1 peptide-pulsed splenocytes, which are antigen-specific target cells, leaving peptides-
unpulsed irrelevant splenocytes intact.
35
 Naïve mice were immunized subcutaneously (s.c.) with PBS, 
OVA protein, WT-FPCN, OT-1-FPCN-C, or OT-1-FPCN-L in the presence of 50 μg of poly (I:C) as 
an adjuvant. At day 14, mice were intravenously (i.v.) injected with 1:1 mixtures, 7 × 10
6
 of each, of 
OT-1 peptides-pulsed (antigen-specific target cells, 5 μM CFSE-labeled, CFSEhi) and unpulsed 
(irrelevant cells, 0.5 μM CFSE-labeled, CFSElow) syngeneic splenocytes. Fourteen to sixteen hours 
later, single cell suspensions were prepared from lymph nodes from each group and antigen-specific 
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CTL activity was evaluated by flow cytometry. Population reduction of CFSE
hi
-labeled OT-1 
peptides-pulsed syngeneic splenocytes was neither observed in PBS, nor WT-FPCN treated group 
(Figure 6, A). In contrast, populations of CFSE
hi
-labeled OT-1 peptides-pulsed syngeneic splenocytes 
were dramatically reduced in groups immunized either with OVA protein, OT-1-FPCN-C, or OT-1-
FPCN-L (Figure 6, A) indicating that target cell lysis by CTL was antigen-specific as expected. With 
increasing doses of antigen conjugated FPCNs, more target cells were lysed ( Supplementary 
Figure 8). Taken together, these data suggest that OT-1 peptides delivered in vivo by FPCNs could 
induce efficient differentiation of antigen-specific CD8
+
 T cells into functional effector cytotoxic T 
cells resulting in selective killing of target cells. 
 
Proliferated OT-2 CD4
+
 T cells were effectively differentiated into functional CD4
+
 Th1 and 
Th2 cells producing IFN-γ/IL-2 and IL-10/IL-13 cytokines, respectively 
In addition to the activation and differentiation of CD8
+
 T cells, DCs are also known to induce 
efficient proliferation and differentiation of CD4
+
 T cells into various helper T cell (Th) subclasses 
depending on distinct expression of cell surface molecules, transcription factors, cytokines, and the 
functional effects they provide for other immune cells.
36 and 37
 For example, CD4
+
 Th1 cells secrete 
interleukin 2 (IL-2) and IFN-γ leading to macrophage activation, inflammation and CD8+ CTL 
activation, while CD4
+
 Th2 cells secrete IL-4, IL-10, and IL-13 leading to B cell differentiation and 
antibody responses. To determine whether the proliferated OT-2 CD4
+
 T cells by DCs following 
antigen delivery via OT-2-FPCNs could be differentiated into functional CD4
+
 T cells, we measured 
their cytokine production. Naïve DCs were pulsed either with OVA protein, WT-FPCN, OT-2-FPCN-
C, or OT-2-FPCN-L for three hours, washed and then co-cultured with OT-2 T cells. After 48-
72 hours, the cytokines in the supernatant were quantified by CBA flex sets and flow cytometry. High 
amounts of Th1 cytokines such as IFN-γ and IL-2 as well as Th2 cytokines such as IL-10 and IL-13 
were observed in the co-culture supernatants of OT-2-FPCN-C or OT-2-FPCN-L pulsed DCs, on 
similar levels compared with that induced by soluble OVA protein, while little or no such cytokines 
were detected from the supernatants of WT-FPCN pulsed DCs (Figure 6, B). The data suggested that 
OT-2 peptides delivered to DCs by FPCNs could induce efficient differentiation of antigen-specific 
CD4
+
 T cells into functional effector CD4
+
 T cells such as Th1 and Th2 cells resulting in secretion of 
various cytokines. 
 
5.4. Conclusion and Discussion 
 
An important aspect of nanotechnology deals with the development of experimental procedures that 
allow reproducible synthesis of nanomaterials with controlled sizes, polydispersities, chemical 
compositions, and shapes. However, the reproducible production of colloidal nanoparticles with 
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uniform sizes, shapes, and compositions, as well as their surface modifications in a precise and 
controlled manner in terms of the quantity and location of substituents still remain challenging 
because of the complex growth-passivation process and their chemical diversity. Biological systems 
have acquired an exquisite level of control through long-term evolution. Ferritin protein cage 
nanoparticles are protein-based supramolecular complexes that have highly symmetric and uniformly 
sized hollow spherical architectures. They are precisely self-assembled from 24 copies of identical 
20 kDa subunits which can be easily and accurately manipulated by genetic modifications and 
chemical bioconjugations.
16, 18 and 19
 Therefore, FPCNs are attractive delivery nanoplatforms for in vivo 
application. In this study, we established antigen delivery protein nanoparticle systems by genetically 
introducing model antigenic peptides, OT-1 or OT-2, either into the interior cavity or onto the exterior 
surface of FPCN. The interior C-terminal end and surface loop region of FPCN were tolerant of the 
peptide insertion potentially offering the sites for insertion of various types of antigenic peptides and 
small protein antigens. All FPCN derivatives carrying OT peptides were efficiently phagocytosed by 
DCs and processed within endosomes. Processed OT-1 and OT-2 peptides within endosomes were 
successfully presented on the surface of DCs and induced sufficient proliferations of OT-1-specific 
CD8
+
 cells and OT-2-specific CD4
+
 T cells, respectively, both in vitro and in vivo with regular 
dosages. Although we did not observe any significant difference in either CD8
+
 or CD4
+
 T cell 
proliferations at low dosages between OTs-FPCN-C and OTs-FPCN-L configurations in vitro setting, 
we observed less CD4
+
 T cell proliferative responses at much lower dosages in the group where 
antigens were delivered via OT-FPCN-L in comparison to OT-FPCN-C in vivo setting. The loop 
structure of epitopes carried by OT-FPCN-L is located in the middle of the protein sequence and 
inserted epitopes might not be processed as efficiently as the epitopes at the C-terminal by DCs in 
vivo, leading to the decreased antigen-specific T cell proliferation. The positions and configurations 
of antigenic peptides or proteins should be carefully considered prior to the insertion for in vivo 
application. Naïve mice immunized with FPCN carrying OT-1 peptides efficiently differentiate OT-1 
CD8
+
 T cells into functional effector cytotoxic T cells and selectively killed antigen-specific target 
cells. Proliferated OT-2 CD4
+
 T cells were effectively differentiated into functional CD4
+
 Th1 and 
Th2 cells producing IFN-γ/IL-2 and IL-10/IL-13 cytokines, respectively. Since FPCN has additional 
sites available for addressing functional activity or cargo transport into the system,
18 and 19
 we are 
currently investigating on incorporating various types of adjuvants and DC targeting ligands. In 
addition, by inserting a whole protein antigen (e.g., OVA protein) rather than T cell antigenic peptides 
(e.g., OT-1 or OT-2) shown here will further provide a capability of FPCN delivery system in 
inducing humoral immunity. Although current vaccines mainly work by inducing neutralizing 
antibodies, strong and functional T cell immunity is required in many infectious diseases as well as in 
cancers and our results show such potential of FPCNs in efficient inducer of T cell immunity. The 
approach and assay systems described here may be applied to other nanocarriers, such as polymer and 
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inorganic nanoparticles as well as various protein cage nanoparticles including FPCN, carrying a 
variety of antigenic peptides, offering a new paradigm for DC-based vaccine development. 
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Figure 1. Antigen-specific T cell proliferations and subsequent immune responses induced by ferritin 
protein cage nanoparticles (FPCNs) carrying OT peptides. 
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Figure 2. (A) Schematic representation of antigenic peptide addition to the C-termini of FPCN. (B) 
Molecular mass measurements of the dissociated subunits of OT-1-FPCN-C (calc, 21,270.4 Da; obs, 
21,270.0 Da, bottom) and OT-2-FPCN-C (calc, 22,081.1 Da; obs, 22,080.5 Da, top). (C) Size 
exclusion elution profiles of WT- (bottom), OT-1- (middle) and OT-2-FPCN-C (bottom). The 
samples were loaded onto a 10 × 300 mm superpose 6 size exclusion column, which had been pre-
equilibrated with 50 mM phosphate and 100 mM NaCl (pH 6.5) and then eluted with the same buffer 
at a rate of 0.5 mL/min. (D) Transmission electron micrographic (TEM) image of 2% uranyl acetate 
stained OT-1-FPCN-C (left) and OT-2-FPCN-C (right). 
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Figure 3. Dendritic cells uptake various FPCNs by phagocytosis. DCs harvested from naïve C57BL/6 
mice were incubated with each indicated protein labeled with pHrodo either at 4 °C (open histograms) 
or 37 °C (shaded histograms) for 2 hours and data were analyzed by flow cytometry. Percentage of 
cells showing positive fluorescence is indicated in each histogram. 
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Figure 4. OVA antigen delivered by FPCNs induces OVA-specific T cell proliferation in vitro. (A) 
DCs harvested from naïve C57BL/6 mice were pulsed either with WT-FPCN, OT-1-FPCN-C, OT-1-
FPCN-L at 2 mg/ml, or OVA protein at 1 mg/ml for 3 hours. The DCs were washed and then co-
cultured with CFSE-labeled OT-1 T cells at a ratio of 1:3. Four days later, the proliferation of OVA-
specific CD8+ T cells was measured by flow cytometry. (B) Same as in A, but the DCs were pulsed 
either with OT-2-FPCN-C or OT-2-FPCN-L at 2 mg/ml and co-cultured with CFSE-labeled OT-2 T 
cells. The proliferation of OVA-specific CD4+ T cells was measured by flow cytometry. 
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Figure 5. OVA antigen delivered by FPCNs induces OVA-specific T cell proliferation in vivo. (A) 
Naïve C57BL/6 mice were adoptively transferred with CFSE-labeled OT-1 T cells and on the next 
day, they were immunized s.c. either with PBS, 100 μg of OVA protein, 50 μg of WT-FPCN, OT-1-
FPCN-C, or OT-1-FPCN-L in the presence of an adjuvant. Three days later, the proliferation of OVA-
specific CD8+ T cells was measured by flow cytometry. (B) Same as in A, but mice were adoptively 
transferred with CFSE-labeled OT-2 T cells and were immunized either with PBS, 500 μg of OVA 
protein, 250 μg of OT-2-FPCN-C or OT-2-FPCN-L. The proliferation of OVA-specific CD4+ T cells 
was measured by flow cytometry. 
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Figure 6. OVA antigen delivered by FPCNs induces the differentiation of functional effector T cells. 
(A) Naïve C57BL/6 Mice were immunized s.c. either with PBS, 100 μg OVA protein, 50 μg of WT-
FPCN, OT-1-FPCN-C, or OT-1-FPCN-L in the presence of an adjuvant. After 14 days, these mice 
were intravenously injected with CFSE-labeled syngeneic splenocytes pulsed with (CFSEhi) or 
without (CFSElow) OT-1 peptide. OVA-specific CD8+ T cell cytotoxicity was measured by flow 
cytometry. (B) DCs harvested from naïve C57BL/6 mice were pulsed either with WT-FPCN, OT-2-
FPCN-C, OT-2-FPCN-L at 2 mg/ml, or OVA protein at 1 mg/ml for 3 hours. The DCs were washed 
and then co-cultured with OT-2 T cells at a ratio of 1:3 for 48-72 hours. IFN-γ, IL-2, IL-10 and IL-13 
production was measured by CBA assay. 
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Figure S1. (A) Schematic representation of antigenic peptide insertion into the loop region of FPCN. 
(Molecular mass measurements of the dissociated subunits of OT-1-FPCN-L (calc, 21,239.2 Da; obs, 
21,239.5 Da, bottom) and OT-2-FPCN-L (calc, 22,239.2 Da; obs, 22,239.5 Da, top). (C) Size 
exclusion elution profiles of WT- (bottom), OT-1-(middle) and OT-2-FPCN-L (bottom). The samples 
were loaded onto a 10 x 300 mm superose 6 size exclusion column, which had been pre-equilibrated 
with 50 mM phosphate and 100 mM NaCl (pH 6.5) and then eluted with the same buffer at a rate of 
0.5 mL/min. (D) Transmission electron micrographic (TEM) image of 2 % uracyl acetate stained OT-
1-FPCN-L (left) and OT-2-FPCN-L (right).  
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Figure S2. Zeta potential measurements of wt and OT peptide inserted FPCNs. Mean values of zeta 
potential are -19.4, -20.9, -28.6, -25.4, and -28.0 mV for wt FPCN, OT-1-FPCN-L, OT-2-FPCN-L, 
OT-1-FPCN-C, and OT-2-FPCN-C, respectively.  
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Figure S3. Dynamic light scattering measurements of wt and OT peptide inserted FPCNs. Mean 
diameters are 13.1, 12.8, 13.5, 13.6, and 13.1 nm for wt FPCN, OT-1-FPCN-L, OT-2-FPCN-L, OT-1-
FPCN-C, and OT-2-FPCN-C, respectively.  
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Figure S4. OVA antigen delivered by FPCNs induces OVA-specific T cell proliferation in vitro. 
Dose-dependent OVA-specific T cell proliferation in vitro. DCs harvested from naïve C57BL/6 mice 
were pulsed with different doses of FPCNs as indicated for 3 hours. The DCs were washed and then 
co-cultured either with CFSE-labeled OT-1 (A) or OT-2 (B) T cells at a ratio of 1:3. Four days later, 
the proliferation of OVA-specific T cells was measured by flow cytometry.   
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Figure S5. (A) Schematic representation of OT-2’ peptide addition to the C-termini or insertion into 
the loop region of FPCN. (B) Molecular mass measurements of the dissociated subunits of OT-2’-
FPCN-C (calc 22,010.1 Da; obs, 22,010.5 Da, top) and OT-2’-FPCN-L (calc 22,168.3 Da; obs, 
22,169.0 Da, bottom).  (C) Size exclusion elution profiles of WT-(bottom), OT-2’-FPCN-L (middle) 
and OT-2’-FPCN-C (top). The samples were loaded onto a 10 x 300 mm superpose 6 size exclusion 
column, which had been pre-equilibrated with 50 mM phosphate and 100 mM NaCl (pH 6.5) and then 
eluted with the same buffer at a rate of 0.5 mL/min. (D) Transmission electron micrographic (TEM) 
image of 2% uracyl acetate stained OT-2’-FPCN-L (left) and OT-2’-FPCN-C (right).  
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Figure S6. FPCNs carrying OT-2 epitope with one amino acid deletion does not induce T cell 
proliferation in vitro. DCs harvested from naïve C57BL/6 mice were co-cultured with CFSE-labeled 
OT-2 T cells at a ratio of 1:10 in the presence of indicated proteins at 1 μM. Four days later, the 
proliferation of OVA-specific T cells was measured by flow cytometry.  
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Figure S7. OVA antigen delivered by FPCNs induces dosage-dependent OVA-specific T cell 
proliferation in vivo. (A) Naïve C57BL/6 mice were adoptively transferred with CFSE-labeled OT-1 
T cells and on the next day, they were immunized s.c. either with PBS, 100 μg OVA protein, 50 μg of 
WT-FPCN, and OT-1-FPCN-C or OT-1-FPCN-L at indicated dosages in the presence of an adjuvant. 
Three days later, the proliferation of OVA-specific CD8+ T cells was measured by flow cytometry. (B) 
Same as in A, but mice were adoptively transferred with CFSE-labeled OT-2 T cells and were 
immunized either with indicated dose of OT-2-FPCN-C or OT-2-FPCN-L. The proliferation of OVA-
specific CD4+ T cells was measured by flow cytometry after three days.  
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Figure S8. OVA antigen delivered by FPCNs induces the differentiation of functional effector T cells. 
Naïve C57BL/6 mice were immunized s.c. either with PBS, 100 μg of OVA protein, 500 μg of WT-
FPCN, OT-1-FPCN-C, or OT-1-FPCN-L in the presence of an adjuvant. After 14 days, the mice were 
intravenously injected with CFSE-labeled syngeneic splenocytes pulsed with (CFSE
hi
) or without 
(CFSE
low
) OT-1 peptide. OVA-specific CD8+ T cell cytotoxicity was measured by flow cytometry.  
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Chapter 6. Lumazine Synthase Protein Nanoparticle-Gd(III)-DOTA 
Conjugate as a T1 contrast agent for high-field MRI. 
 
6.1. Introduction 
 
With the applications of MRI in higher magnetic fields (>7 T) both in preclinical and clinical settings 
increasing, there are needs to develop MRI contrast agents with improved relaxivity at higher 
magnetic fields. From MRI perspective, the advantage of higher magnetic field is attractive, as it is 
expected to drastically increase signal to noise ratio (SNR) and resolution
1,2
. However, it is generally 
observed that spin-lattice time (T1) increases and converges for different tissues as the magnetic field 
strength increases, which reduces contrast for T1-weighted exams using the same imaging parameters 
used at conventional 1.5 or 3 T
3,4
. As contrast to noise ratio (CNR) is critical for the sensitivity and 
specificity of MRI exams, this reduction of inherent T1 contrast necessitates the development of 
efficient in vivo compatible positive contrast agent with good relaxivity characteristics at higher 
magnetic field
5,6,7,8
. Protein cage nanoparticles, including ferritins, encapsulins, and virus-like 
particles (VLPs), have been widely used as nanoscale delivery vehicles for diagnostic and/or 
therapeutic reagents
9,10,11,12,13,14,15,16,17,18,19,20,21
 as they not only have well-defined structure and size, but 
also consist of biocompatible and biodegradable biomaterials, polypeptides
22
. The highly symmetrical 
and uniformly composed architecture of protein cage nanoparticles allow them to be manipulated in a 
highly controlled manner, resulting in the production of reproducible nanoscale multifunctional 
particles
9,10,11,12,13,14,15,16,17,18,19,20,21
. VLPs have been extensively studied as supramolecular templates 
for the conjugation of small molecule contrast agents, such as the chelated paramagnetic gadolinium 
ion (Gd(III)), which is frequently used as a positive contrast agent for magnetic resonance imaging 
(MRI)
23,24,25,26,27
. Macromolecule (such as protein)-based contrast agents are known to yield 
significantly higher r1 relaxivity due to decreased local motion and increased correlation time
28,29,30
; 
however in vivo applicable positive contrast agents, which maintain considerably enhanced r1 
relaxivity (>10 mM−1s−1) with an acceptable r1/r2 ratio (0.5 ~ 1) at high magnetic field (7 T), are a 
rarity
8,31,32,33,34
. In the present study, we used lumazine synthase, isolated from the hyperthermophile 
Aquifex aeolicus (AaLS), as a nanoscaled template for T1 contrast conjugates as illustrated in Fig. 1A 
and evaluated its potential as an in vivo MR contrast agent at the magnetic field strength of 7 T. AaLS 
is composed of 60 identical subunits that form an icosahedral capsid architecture (T = 1 state) with 
respective exterior and interior diameters of 15.4 nm and 9 nm35. AaLS is known to catalyze the 
penultimate step of riboflavin biosynthesis within cells
36
. The structural robustness and functional 
plasticity of AaLS make it an attractive candidate for a versatile bio- and nanotechnological 
platform
37,38,39,40,41,42,43,44
. Its hollow spherical architectures have been used as templates for the 
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encapsulation of functional proteins
37,43,44,45,46
 and the biomimetic synthesis of iron oxides
44
, as well as 
delivery vehicles of therapeutic and/or diagnostic reagents
32,34
. AaLS has also been engineered into 
multifunctional building blocks for fabricating uniform layer-by-layer (LbL) assemblies using non-
covalent interactions between surface-displayed hexahistidine and Ni-NTA of AaLS
39
. For our 
application, Gd(III)-chelating agent complexes were attached at position 108 with cysteine (R108C), 
which is known to be exposed on the exterior surface of AaLS. Experimentally, Gd(III)-DOTA-AaLS 
were characterized by mass spectroscopy (MS) to ensure that AaLS was modified with only one 
Gd(III)-DOTA complex per subunit. Transmission emission microscopy (TEM) was used 
subsequently to ensure that the cage architecture and stoichiometry of AaLS is not significantly 
altered in the Gd complex conjugation. Next, r1 and r2 MR relaxivities were measured at 1.4 T and 7 
T with multiple Gd concentration phantoms. In vivo imaging experiments were performed at the 
magnetic field strength of 7 T using a tumor bearing mouse, before and after the injection of Gd(III)-
DOTA-AaLS-R108C. Observed signal behaviors were directly compared with the corresponding 
results from the injection of conventional Gd-DOTA (DOTAREM) for both vasculature and tumor 
regions. 
 
6.2. Material and methods 
 
Gd(III)-DOTA-AaLS-R108C as MRI contrast agent (MRI CA) 
AaLS does not have sufficiently large inter-subunit spaces for Gd(III)-chelating agent complexes to 
freely diffuse into its interior cavity. Thus, to attach Gd(III)-chelating agent complexes in a site-
specific and number controlled manner, we substituted the arginine residue at position 108 with 
cysteine (R108C), which is known to be exposed on the exterior surface of AaLS and readily to be 
used as a site for the attachment of small molecules
47,48,49
. To fully saturate the chelating agents 
(maleimido-monoamide-DOTA (DOTA-mal)) with Gd(III), they were incubated with an excess of 
Gd(III) prior to conjugation to AaLS. Subsequently, AaLS was treated with 3 mol equivalents of 
Gd(III)-DOTA-mal for attachment at room temperature with vigorous shaking overnight (Fig. 1A). 
Unreacted Gd(III)-DOTA-mal were removed by extensive dialysis with multiple changes of buffer. 
The extent of the conjugation was determined by subunit mass measurements using electrospray 
ionization time-of-flight mass spectrometry (ESI-TOF; Xevo G2 TOF). 
 
Cell and animal models 
Squamous cell carcinoma (SCC)-7 cells were cultured in RPMI1640 medium containing 10% (v/v) 
fetal bovine serum and 1% (w/v) penicillin-streptomycin at 37 °C under conditions of 5% CO2. To 
generate a tumor-bearing mice model, SCC-7 (1 ×  106) cells in phosphate-buffered saline (PBS) were 
injected subcutaneously into the right flank of six-week-old female BALB/c nude mice weighing 20–
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25 g (Harlan Laboratories). When the tumor volume reached approximately 100 mm3, the mice were 
used for in vivo MR imaging. All animal studies were performed in compliance with the guidelines of 
the local ethics committee for animal care and use, and were approved by the Institutional Animal 
Care and Use Committee of Ulsan National Institute of Science and Technology.. 
 
Relaxivity Measurements 
We measured the T1 and T2 relaxation times of the Gd(III)-DOTA-AaLS under 1.4 T (Bruker 
Minispec MQ60 TD-NMR, 60 MHz) and 7 T (Bruker BioSpec 70/16 US, 300 MHz) magnets. At 
60 MHz, the T1 relaxation times of the Gd(III)-DOTA-AaLS were measured using the inversion 
recovery (IR) method with the IR delay ranging from 0–20000 ms. T2 relaxation times were measured 
with a CPMG sequence with echo spacing (TE) of 1 ms and recycling time (TR) of 1.5 s. At 300 MHz, 
the T1 relaxation time was estimated using a sequence of rapid acquisition with relaxation 
enhancement (RARE) at variable repetition times; 10 TR values of 20–5000 ms were used with echo 
time (TE) of 7.6 ms. The T2 relaxation time was measured using a multi-slice multi-echo (MSME) 
method at TR of 5000 ms with 50 TE values in the range of 20–1000 ms. The proton relaxivities (r1 : 
longitudinal relaxivity and r2 : transverse relaxivity) were determined by measuring the T1 relaxation 
times and T2 relaxation times of six different Gd concentrations of Gd(III)-DOTA-AaLS-R108C 
(0.074, 0.037, 0.0185, 0.00925, 0.004625, and 0 mM). Both relaxivities r1 and r2 were calculated from 
the slope of the relaxation rate R1 (1/T1) and R2 (1/T2) as a function of concentration (mM) of contrast 
agent, respectively. We previously demonstrated that the relaxivities of protein cage nanoparticles 
conjugated with Gd(III)-chelating agent can be determined by measuring the T1 relaxation time and 
corresponding Gd(III) concentrations
23
. The relaxivities of Gd(III)-DOTA-AaLS-R108C were 
calculated using the linear relaxivity equation used in a previous study
23,26
. The proton relaxivities of 
saline solutions with untreated AaLS-R108C at identical concentrations were determined, as AaLS 
may also give T1 enhancement as well. 
 
In vivo imaging of tumor-bearing mice 
All tumor-bearing mice weighing 20–25 g (tumor volume: ~100 mm3) were scanned using 7 T MRI 
(Bruker Biospec) with a transceiver RF volume coil (diameter: 40 mm) for the mouse body, 
maintained under anesthesia with 1.0–1.5% isoflurane. Radiofrequency power and receiver 
adjustments were continuously maintained for each scan. Four mice were examined to investigate the 
vasculature imaging capabilities and the tumor accumulation efficacy of Gd(III)-DOTA-AaLS-R108C 
at high field (7 T) and two mice in the control group were assessed using Gd-DOTA (DOTAREM) as 
a reference. Four mice were injected intravenously with 350 μl of Gd(III)-DOTA-AaLS-R108C 
(concentration: 17.143 mM) as a bolus into the tail vein. Also in the same manner, two mice were 
injected intravenously with 350 μl of DOTAREM (concentration: 17.857 mM) as a bolus into the tail 
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vein for the direct comparisons. For the longitudinal and direct comparison of the vasculature imaging 
capability and delivery efficacy of Gd(III)-DOTA-AaLS-R108C to the tumor region, three 
dimensional (3D) MR angiography (MRA) and T1-mapping were adopted at six time points (1, 2, 3, 7, 
12, and 30 h) after the intravenous injection of the contrast agent at a dose of 0.3 mmol/kg. To this end, 
a 3D-Fast Low-Angle Shot (FLASH) and a RARE with variable repetition time TR (RAREVTR) 
sequence were used for a high-resolution angiogram and T1-map, respectively. MR parameters were 
set as follows: TR = 13 ms, TE = 2.1 ms, flip angle = 20°, FOV = 30 ×  30 ×  30 mm3, matrix 
size = 256 ×  256 ×  256 for 3D-FLASH; TR = 8 values in the range of 280–5000 ms, TE = 6.0 ms, field 
of view (FOV) = 30 ×  30 mm2, slice thickness = 1 mm, matrix size = 128 ×  128 for RAREVTR T1 
measurements. MRA were reconstructed using maximum intensity projection (MIP) protocol with 
Bruker Paravision software (PV6) and T1-maps were generated by a mono-exponential fitting method 
(Matlab, R2013a, The MathWorks Inc., USA). 
 
6.3. Results 
 
Characterization of Gd(III)-DOTA-AaLS-R108C 
The extent of the Gd(III)-DOTA-conjugation was determined by ESI-TOF MS, following the 
dissociation of Gd(III)-DOTA-mal treated AaLS-R108C. The subunit molecular masses of AaLS-
R108C and Gd(III)-DOTA-mal treated AaLS-R108C were determined to be 27415.0 and 28095.0 Da, 
respectively, which are in an excellent agreement with the corresponding calculated values of 27413.6 
and 28096.9 Da and only one mass peak was observed (Fig. 1B). Mass spectrometric data indicated 
that all subunits of AaLS-R108C were modified with only one Gd(III)-DOTA complex (60 Gd(III)-
DOTA per cage). The Gd-content of Gd(III)−DOTA conjugated AaLS-R108C was independently 
measured with inductively coupled plasma-mass spectrometry (ICP-MS) and the Gd-content was 
determined to be 0.86 Gd(III) per subunit, which is slightly lower than the value determined by MS 
probably due to slight sample loss during ICP-MS sample preparation
23
. To avoid overestimation of 
the relaxivity of Gd(III)-DOTA–conjugated AaLS-R108C (Gd(III)-DOTA-AaLS-R108C), we used 
the Gd content as determined by MS
23
. Gd(III)-DOTA-AaLS-R108C was eluted at the same position 
as untreated AaLS-R108C in size exclusion chromatography (Fig. 1C) and transmission electron 
microscopic images of negatively stained Gd(III)-DOTA-AaLS-R108C showed its intact cage 
architecture with the same size as untreated AaLS (~15 nm in diameter, Fig. 1D). Zeta potential 
measurements revealed that Gd(III)-DOTA-AaLS-R108C had slightly lower negative surface charge 
(−8.2 mV) than that of AaLS-R108C (−5.5 mV) probably due to the introduced Gd(III)-DOTA. These 
results demonstrate that Gd(III)-DOTA-mal conjugation to AaLS-R108C does not significantly alter 
its cage architecture or stoichiometry. 
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Relaxivity measurements with phantoms 
The T1 relaxation times became shorter under both 1.4 T and 7 T, as the Gd(III) concentrations 
increased (Fig. 2A-1) suggesting that the Gd(III)-DOTA-AaLS-R108C supramolecular template 
accelerated the recovery of net magnetization. Corresponding T2 relaxation times also decreased as 
Gd(III) concentrations increased (Fig. 2A-2). Gd(III)-DOTA-AaLS-R108C showed higher T1 
relaxivity (r1 = 30.24 mM
−1
s
−1
, r2 = 41.42 mM
−1
s
−1
, Fig. 2A-3) per Gd(III) under 1.4 T (37 °C) than did 
free Gd(III)-chelating agents (4–5 mM−1s−1). Although the T1 relaxivity of Gd(III)-DOTA-AaLS-
R108C decreased (r1 = 16.49 mM
−1
s
−1
, r2 = 31.86 mM
−1
s
−1
, Fig. 2C-3) under high magnetic field (7 T, 
room temp.), the measured r1/r2 values of Gd(III)-DOTA-AaLS-R108C were 0.73 and 0.52 for 1.4 T 
and 7 T, respectively, indicating that Gd(III)-DOTA-AaLS-R108C remains as the optimal T1 contrast 
agent at 7 T
23,26
. The T1 and T2 relaxation times measurements with increasing concentration of 
untreated AaLS-R108C at identical experimental conditions were shown in Fig. 2B-1 for 1.4 T. 
Corresponding relaxations times measurements were shown in Fig. 2D-1 for 7 T. The relaxivities of 
untreated AaLS-R108C at 1.4 T (r1 = 0.37 mM
−1
s
−1
, r2 = 1.29 mM
−1
s
−1
, Fig. 2B-3) and 7 T 
(r1 = 1.02 mM
−1
s
−1
, r2 = 3.14 mM
−1
s
−1
, Fig. 2D-3) were determined as reference. To evaluate the 
potential usage of Gd(III)-DOTA-AaLS-R108C as an in vivo T1 contrast agent at high magnetic field, 
we captured T1-weighted MR images of the phantom using a volume coil with a 7 TMRI scanner 
using a RAREVTR sequence at 4 TR values (100, 500, 1000, and 2000 ms). T1-weighted in vitro 
phantom images of PBS control (S1A), AaLS-R108C only (S1B) and Gd(III)-DOTA-AaLS-R108C 
with increasing concentrations (S1C) were shown in supporting Fig. 1. While the MR signal 
intensities of Gd(III)-DOTA-AaLS-R108C were significantly enhanced at short TRs (500 and 
1000 ms), those of the PBS control and AaLS-R108C were not, as shown in supporting Figure S1C, 
S1A, and S1B, respectively. As the Gd concentration of Gd(III)-DOTA-AaLS-R108C is increased, 
the accelerated R1 values of Gd(III)-DOTA-AaLS-R108C led to contrast enhancement resulting in 
brighter images at short TRs as shown in Figure S1C. For the comparisons with conventional 
DOTAREM, saturation recovery signals with RAREVTR at multiple TR values were plotted together, 
where the Gd concentrations (0.0185, 0.037, and 0.074 mM) were kept same for both Gd(III)-DOTA-
AaLS-R108C and DOTAREM as shown in S1D. Increased R1 values were apparent for Gd(III)-
DOTA-AaLS-R108C at the same concentration, which led to enhanced r1 relaxivity over conventional 
DOTAREM at 7 T. 
 
In vivo characterizations 
3D MR angiograms and T1 maps of tumor-bearing mice were generated to evaluate both the 
feasibility of MR angiography and the tumor accumulation efficacy using newly developed Gd(III)-
DOTA-AaLS-R108C. Identical experiments and analysis were repeated with conventional 
DOTAREM for direct comparisons. From these MR data, region of interest (ROI) analysis was also 
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employed to measure regionally averaged T1 values and corresponding signal enhancement. The 
decreasing trend in T1 values of the tumor region of mice was consistently observed after the time 
point of ~7 h post-Gd(III)-DOTA-AaLS-R108C injection. Figure S2A and S2B illustrates this, 
showing T1 maps before and 30 h after the injection. Supplementary Figure S2C shows the 
corresponding T1 fitting results at both time points, respectively. Decreased T1 values in the tumor 
region could clearly be observed 30 h after the injection of Gd(III)-DOTA-AaLS-R108C both with T1 
maps and corresponding raw T1 fitting results. MIP images of tumor bearing mice taken at sequential 
time points (pre, post, 2 h, 7 h, 12 h, and 30 h) after the injection of Gd(III)-DOTA-AaLS-R108C were 
plotted in the first column of Fig. 3A. Immediately after the injection, blood vessels were brightened 
as the T1 values in the vessels significantly decreased due to the contrast agent injection. As time 
progressed, positive contrast in blood vessel diminished and ~7 h after the injection, the positive 
contrast in the tumor region started to appear. T1 shortening of tumor regions was further confirmed 
by T1 maps shown in the second column of Fig. 3B and the median-shift of the T1 histogram 
distribution of the whole 3D tumor volume, shown in the third column of Fig. 3C. Identical analysis 
was performed with conventional DOTAREM as shown in Fig. 3D–F. Blood vessels were also 
brightened right after the injection and dimming. Positive T1 contrast in the tumor region was apparent 
up to 2 h after the injection of DOTAREM, and positive T1 contrast diminished and the T1 values were 
restored to original values 7 h post-injection. Longitudinal maximum intensity projection (MIP) 
images before and after the injections of Gd(III)-DOTA-AaLS-R108C (n = 4) and DOTAREM (n = 2) 
were shown in supporting Figure S3. Figure 4A,B present ROI analysis, showing the temporal trend 
of signal enhancement measured in the arterial region after injection with Gd(III)-DOTA-AaLS-
R108C and conventional DOTAREM. The signal enhancement trend in artery caused by both agents 
had a similar pattern. Directly after injection, maximal arterial signal enhancements were obtained 
from both contrast agents, this enhancement diminished as time progressed. A slower decreasing 
slope of arterial signal enhancement with Gd(III)-DOTA-AaLS-R108C than that from conventional 
DOTAREM was observed presumably from the elongated intravascular residence time of Gd(III)-
DOTA-AaLS-R108C due to its size and hydrophilic surface. No meaningful arterial signal 
enhancements were observed 7 h and 30 h after injection with DOTAREM and Gd(III)-DOTA-AaLS-
R108C, respectively. Temporal variations of T1 values in both tumor and muscle on the other side of 
flank after injection with Gd(III)-DOTA-AaLS-R108C and DOTAREM were presented in Fig. 4C,D. 
For Gd(III)-DOTA-AaLS-R108C, the T1 value in the tumor slowly decreased in the first 2 h post-
injection, and started to show a statistically significant change from 7 h post-injection (p < 0.05), 
while T1 in muscle showed no significant change at any time point. For DOTAREM on the other hand, 
the T1 value in the tumor reached the minimum value at the initial time point right after the injection, 
and then rapidly rebounded and returned to its original level at 7 h. T1 in muscle showed a similar 
trend to T1 in tumor, with relatively reduced changes of T1 values at each time point. 
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6.4. Conclusion and Discussion 
 
The high T1 relaxivity of Gd(III)-DOTA-AaLS-R108C may result from the slow tumbling rate of its 
large cage architecture
28
. Most previous studies performed with VLPs and protein complexes as 
supramolecular conjugates haven shown relaxivities of 10–50 mM−1s−1, depending on experimental 
conditions
23,24,25,26,27
. When compared with experiments of Gd(III)-DOTA chelating agent conjugates 
we have performed previously, our measured value at 1.4 T (30.24 mM−1s−1) was slightly lower than 
that of large VLPs, P22 K118C WB (35.8 mM−1s−1), but slightly higher than small sized ferritin 
(19.9 mM−1s−1)23. The T1 enhancement ability (r1/r2) tends to decrease significantly as the magnetic 
field is increased and often represents a major problem when applying macromolecular contrast 
agents at high field. The measured r1/r2 ratio (0.52) of Gd(III)-DOTA-AaLS-R108C at high magnetic 
field makes it attractive as a T1 contrast agent at 7 T. It appears that the molecular hindrance 
mechanism and resulting dynamics of Gd(III)-chelating agent complexes conjugated to lumazine 
synthase determine overall relaxation characteristics, but the exact explanation is unresolved at this 
point. Future relaxation simulation may shed more light on these experimental observations. In vivo 
MIP images after the injection of Gd(III)-DOTA-AaLS-R108C show clearly defined vasculature, as 
shown in Fig. 3A. Compared with Gd-DOTA, which exhibited fast leakage in a rodent model of 
vasculature imaging, intravascular Gd(III)-DOTA-AaLS-R108C appears to provide robust MR 
angiography at 7 T. The temporal trend of signal enhancement in the arterial region shows that 
optimal signal enhancement of the vasculature is achieved within 2 h of intravenous injection of 
Gd(III)-DOTA-AaLS-R108C. As the longitudinal relaxation rate (R1) in tumor is generally known to 
be proportional to Gd(III) concentration, the absolute T1 (1/R1) map of tumor and muscle regions on 
the other hind leg enables the monitoring of temporal variations in Gd(III) accumulation of both 
regions, with minimized animal repositioning and slice mismatch errors occurring in longitudinal 
follow up studies. In other words, decreasing absolute T1 values in tissue should reflect increasing 
Gd(III) concentration of corresponding region. The T1 value of the tumor decreased after the injected 
Gd(III)-DOTA-AaLS-R108C gradually migrated to the tumor region. A statistically significant 
decline in T1 value was observed 7 h post-injection, which coincides with a significant drop in signal 
enhancement in the arterial region. Compared to the short retention time (<2 h) of DOTAREM, due to 
its relatively small size and low molecular weight
45
, Gd(III)-DOTA-AaLS-R108C showed a 
prolonged retention time in tumor. A consistent T1 value in the other hind leg muscle away from the 
tumor supported the tumor-specific migration of Gd(III)-DOTA-AaLS-R108C, presumably due to the 
enhanced permeability and retention effects of the tumor
46,51
. These observations could be considered 
as the results of the abnormal characteristics of tumor tissue. In general, it is known that tumor tissues 
exhibit leaky vasculature and ineffective lymphatic drainage due to rapid and defective angiogenesis
52
. 
Hence, the tumor vasculature easily permits adequately sized macromolecules in plasma to escape 
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from the tumor vessels and accumulate in tumor tissue for a specific time
51
. Meanwhile, although the 
long retention time of Gd(III)-DOTA-AaLS-R108C in tumor could be a strength in applications 
relating to anti-tumor therapy or drug delivery, it may raise toxicity concerns due to the release of free 
Gd(III) from prolonged retention, and further in vivo toxicity study should be followed. This study 
demonstrates that newly developed Gd(III)-DOTA-AaLS-R108C could be successfully applied as a 
positive T1 MR contrast agent at high field, and utilized as a high-resolution vasculature imaging 
agent, active within 2 h of injection. Its prolonged retention time in tumors may be a key advantage 
for a potential theranostic nanoplatform, as well as for future scientific investigations of optimized 
MRI T1 contrast agent at higher magnetic field. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
 
 
 
Figure 1. Surface and ribbon diagram representations of AaLS-RC (PDB: 1HQK) and site-specific 
conjugations of Gd(III)-DOTA (red dots) to the exterior surface of AaLS-R108C. (B) Molecular mass 
measurements of dissociated subunits of untreated AaLS-R108C (bottom) and Gd(III)-DOTA-AaLS-
R108C (top). Calculated and observed molecular masses are indicated. (C) Size exclusion profiles of 
untreated AaLS-R108C (bottom) and Gd(III)-DOTA-AaLS-R108C (top). (D) Transmission electron 
microscopic image of negatively stained untreated AaLS-R108C (right) and Gd(III)-DOTA-AaLS-
R108C (left) with 2% uranyl acetate. 
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Figure 2. Measurements of T1 and T2 relaxation times of Gd(III)-DOTA-AaLS-R108C at 1.4 T (A-
1,A-2) and 7 T (C-1,C-2). The inverse values of the T1 and T2 relaxation times (R1 and R2) are 
plotted against Gd(III) concentration, whose slopes determine corresponding relaxivities (r1 and r2) 
for 1.4 T (A-3) and 7 T (C-3). Corresponding relaxation times and relaxivities were measured for 
untreated AaLS solutions and shown for 1.4 T (B-1–B-3) and 7 T (D-1–D-3). 
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Figure 3. Representative (A) 3D MIP images, (B) T1-maps, and (C) Histogram of T1 values at 
various time points after injection of Gd(III)-DOTA-AaLS-R108C. Representative (D) 3D MIP 
images, (E) T1-maps, and (F) Histogram of T1 values at various time points after injection of 
conventional Gd-DOTA. 
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Figure 4. Temporal signal enhancement in arterial region after injection of (A) Gd(III)-DOTA-AaLS-
R108C and (B) Gd-DOTA. (C,D) Temporal variation of median T1 values in tumor and muscle 
regions after the injection of Gd(III)-DOTA-AaLS-R108C and Gd-DOTA, respectively. (* represents 
statistical significance with p < 0.05). 
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Figure S1. T1-weighted in vitro phantom images of PBS control (A), AaLS-R108C only (B) and 
Gd(III)-DOTA-AaLS-R108C with increasing concentrations (C), all at 7 T and obtained using a 
RAREVTR sequence at 4 TR values (100, 500, 1000, and 2000 ms). For the comparison with 
conventional DOTAREM, saturation recovery signal with RAREVTR at multiple TR values were 
plotted together at a few identical Gd concentrations (0.0185, 0.037, and 0.074 mM) of Gd(III)-
DOTA-AaLS-R108C and DOTAREM (D). Increased R1 values were apparent for Gd(III)-DOTA-
AaLS-R108C. 
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Figure S2. (A,B) Representative T1 map and (C) T1 fittings of ROI over the tumor prior to (blue 
square) and 30 h (red square) post-injection of Gd(III)-DOTA-AaLS-R108C. 
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Figure S3. Longitudinal maximum intensity projection (MIP) images before and after injections of 
Gd(III)-DOTA-AaLS-R108C (n=4) and DOTAREM (n=2) 
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Conclusion  
 
Protein cages are well-defined building blocks in nature. Protein cages are capable of self-assembly 
and contain various sizes with different morphologies. As nature architecture, protein cages have 
many advantages for biomedical applications such as biocompatibility, low cost for purification, well 
defined size and shape, and easy modification. In addition, their quantity and location of substituents 
can be easily controlled. Thus, protein cages have been well utilized in biomedical application with 
such diverse properties as a nanoscale biotemplate. Particularly, ferritin, as hollow spherical 
architecture, can encapsulate functional nanomaterials such as imaging probes and drugs to its internal 
space. The external surface of protein cages is able to carry some molecules such as antibody or 
peptides for specific targeting purpose, indicating protein cages can be utilized in various categories 
of biomedical application. In this study, two types of versatile protein cage architectures, Ferritin and 
Lumazine synthase, were utilized as a template. Ferritin protein could encapsulate image detection 
probes into its hollow cavity by bioconjugation and led specific binding to a cancer cell marker by 
using its antibody conjugated external surface. In order to develop a vaccine model system, ferritin 
proteins were utilized as antigen delivery nanoplatforms. Lumazine synthase was utilized as an 
effective detection agent in MRI system. The assembled design of protein cages provided novel 
functions and mimicked natural functions in nanotechnology. Taken together, protein cages 
containing both functional hollow internal cavity and external surface can enhance drug delivery 
efficiency and biocompatibility as nanomedicines, and as a detectable agent, they are expected to 
make high resolution images for early detection of diseases in vivo. In future study, various protein 
cages need to be investigated in details for realistic theranostic and diagnostic application. 
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